

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/40	A2	(11) International Publication Number: WO 98/24432 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/22210 (22) International Filing Date: 2 December 1997 (02.12.97) (30) Priority Data: 60/031,587 5 December 1996 (05.12.96) US 60/045,716 6 May 1997 (06.05.97) US (71) Applicant (for all designated States except US): SUGEN, INC. [US/US]; 351 Galveston Drive, Redwood City, CA 94063-4720 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): McMAHON, Gerald [US/US]; 1800 Schultz Road, Kenwood, CA 95454 (US). TANG, Peng, Cho [US/US]; 827 Camino Ricardo, Moraga, CA 94556 (US). SUN, Li [CN/US]; 64 Rockharbor Lane, Foster City, CA 94404 (US). TRAN, Ngoc, My [GB/US]; Apartment 6306, 550 Shannon Way, Redwood City, CA 94065 (US). (74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: USE OF INDOLINONE COMPOUNDS AS MODULATORS OF PROTEIN KINASES (57) Abstract The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF INDOLINONE COMPOUNDS AS MODULATORS OF PROTEIN KINASES

DESCRIPTIONRELATED APPLICATIONS

This application relates to U.S. patent application Serial No. 60/031,587, filed December 5, 1996, entitled "Tyrosine, Serine, and Threonine Kinase Modulators and
5 Related Products and Methods for the Treatment of Disease" by McMahon et al. (Lyon & Lyon Docket No. 223/058) and this application also relates to U.S. patent application Serial No. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries
10 and Related Products and Methods for the Treatment of Disease" by Tang et al. (Lyon & Lyon Docket No. 221/187) which is a continuation-in-part application of U.S. patent applications Serial Nos. 08/655,225, filed June 5, 1996, entitled "3-(2'-Halobenzylidenyl)-2-Indoline
15 Compounds for the Treatment of Disease" by Tang et al. (Lyon & Lyon Docket No. 223/299); 08/655,226, filed June 5, 1996, entitled "3-(4'-Dimethylaminobenzylidenyl)-2-Indolinone and Analogues Thereof for the Treatment of Disease" by Tang et al. (Lyon & Lyon Docket No.
20 223/300); 08/655,223, filed June 5, 1996, entitled "3-Heteroaryl-2-Indolinone Compounds for the Treatment of Disease" by Tang et al. (Lyon & Lyon Docket No. 223/301); 08/655,224, filed June 5, 1996, entitled "3-

THIS PAGE BLANK (USPTO)

(2'-Alkoxybenzylidenyl)-2-Indolinone and Analogues
Thereof for the Treatment of Disease" by Tang et al.
(Lyon & Lyon Docket No. 223/302); and, 08/659,191, filed
June 5, 1996, entitled "3-(4'Bromobenzylindenyl)-2-
5 Indolinone and Analogues Thereof for the Treatment of
Disease" by Tang et al. (Lyon & Lyon Docket No.
223/303), all of which are continuations-in-part of U.S.
patent application Serial No. 08/485,323, filed June 7,
1995, entitled "Benzylidene-Z-Indoline Compounds for the
10 Treatment of Disease" by Tang et al. (Lyon & Lyon Docket
No. 223/298) all of which are incorporated herein by
reference in their entirety, including any drawings.

INTRODUCTION

The present invention relates to novel compounds
15 capable of modulating, regulating and/or inhibiting
tyrosine serine, and/or kinase signal transduction. The
present invention is also directed to methods of
regulating, modulating or inhibiting tyrosine theonine
kinases, whether of the receptor or non-receptor class,
20 for the prevention and/or treatment of disorders related
to unregulated tyrosine kinase signal transduction,
including cell proliferative and metabolic disorders.

BACKGROUND OF THE INVENTION

The following description of the background of the
25 invention is provided to aid in understanding the
invention, but is not admitted to be or describe prior
art to the invention.

Protein kinases and protein phosphatases regulate a wide variety of cellular processes including metabolism cell proliferation, cell differentiation, and cell survival by participating in signal transduction pathways. Alterations in the cellular function of a protein kinase or protein phosphatase can give rise to various diseased states in an organism. For example, many types of cancer tumors are associated with increases in the activity of specific protein kinases. Cell and tissue degeneration can also be associated with decreases in the activity of particular protein kinases.

Cellular signal transduction is a fundamental mechanism whereby extracellular stimuli are relayed to the interior of cells. One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of proteins. Phosphorylation of amino acids regulates the activity of mature proteins by altering their structure and function.

Phosphate most often resides on the hydroxyl moiety of serine, threonine, or tyrosine amino acids in proteins. Enzymes that mediate phosphorylation of cellular effectors fall into two classes. While protein phosphatases hydrolyze phosphate moieties from phosphoryl protein substrates, protein kinases transfer a phosphate moiety from adenosine triphosphate to protein substrates. The converse functions of protein kinases and protein phosphatases balance and regulate the flow of signals in signal transduction processes.

Protein kinases are divided into two groups - receptor and non-receptor type proteins. Receptor protein kinases comprise an extracellular region, a transmembrane region, and an intracellular region.

5 Part of the intracellular region of receptor protein kinases harbors a catalytic domain. While non-receptor protein kinases do not harbor extracellular or transmembrane regions, they do comprise a region similar to the intracellular regions of their receptor
10 counterparts.

Protein kinases are divided further into three classes based upon the amino acids they act upon. Some incorporate phosphate on serine or threonine only, some incorporate phosphate on tyrosine only, and some
15 incorporate phosphate on serine, threonine, and tyrosine.

In an effort to discover novel treatments for diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit
20 the function of protein kinases. Some small organic molecules form a class of compounds that modulate the function of protein kinases. Examples of molecules that have been reported to inhibit the function of protein kinases are bis monocyclic, bicyclic or heterocyclic
25 aryl compounds (PCT WO 92/20642, published November 26, 1992 by Maguire et al.), vinylene-azaindole derivatives (PCT WO 94/14808, published July 7, 1994 by Ballinari et al.), 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No. 5,330,992), styryl compounds (U.S. Patent No.

5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427, published February 17, 1994 by Denny et al.), tricyclic polyhydroxylic compounds (PCT WO 92/21660, published December 10, 1992 by Dow), and benzylphosphonic acid compounds (PCT WO 91/15495, published October 17, 1991 by Dow et al). The compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein kinase inhibitors only weakly inhibit the function of protein kinases. In addition, many inhibit a variety of protein kinases and will therefore cause multiple side-effects as therapeutics for diseases.

Some indolinone compounds, however, form classes of acid resistant and membrane permeable organic molecules. WO 96/22976, published August 1, 1996 by Ballinari et al., describes hydrosoluble indolinone compounds that harbor tetralin, naphthalene, quinoline, and indole substituents fused to the oxindol ring. These bicyclic substituents are in turn substituted with polar moieties including hydroxylated alkyl, phosphate, and ether moieties. U.S. Patent Application Serial Nos. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang et al. (Lyon &

Lyon Docket No. 221/187) and 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang et al. (Lyon & Lyon Docket No. 223/298) and International Patent Publication WO 96/22976, published August 1, 1996 by Ballinari et al., all of which are incorporated herein by reference in their entirety, including any drawings, describe indolinone chemical libraries of indolinone compounds harboring other bicyclic moieties as well as monocyclic moieties fused to the oxindol ring. Applications 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang et al. (Lyon & Lyon Docket No. 221/187); 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang et al. (Lyon & Lyon Docket No. 223/298), and WO 96/22976, published August 1, 1996 by Ballinari et al., teach methods of indolinone synthesis, methods of testing the biological activity of indolinone compounds in cells, and inhibition patterns of indolinone derivatives.

Despite the significant progress that has been made in developing indolinone based pharmaceuticals, there remains a need in the art to identify the particular structures and substitution patterns that cause inhibition of particular protein kinases and other specified biological activities.

SUMMARY OF THE INVENTION

The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting tyrosine, serine, and/or threonine kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes.

The present invention features indolinone compounds that potently inhibit protein kinases. The data provided herein demonstrates that the compounds of the invention can inhibit tyrosine kinases, serine kinases, and threonine kinases. Given this information, those skilled in the art will be able to target particular disease indications [see Section III - Target Diseases below] based upon the identification of the particular compound either as a tyrosine serine or threonine kinase inhibitor. The invention also features methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds, and methods of preventing and treating abnormal conditions in an organism.

The compounds of the invention represent a new generation of potential cancer therapeutics as they are specific to their target and will subsequently cause few side effects. These properties are welcome improvements over the currently utilized cancer therapeutics that cause multiple side effects and deleteriously weaken patients.

Thus, in a first aspect, the invention features a method for modulating the activity of a protein kinase. The method involves contacting said kinase with an indolinone compound or pharmaceutically acceptable salt thereof demonstrated to have modulating capability in a bioassay corresponding to the kinase being modulated. The protein kinase may be a serine kinase, a threonine kinase, or a tyrosine kinase and may be either a split kinase or a non-split kinase. Typical bioassays are listed in Table 1 and include Flk, EGF, HER2, PCRB, BLOKIN, and rafmak assays. Such assays are known by those skilled in the art to correlate with tyrosine kinase activity, serine kinase activity or threonine kinase activity depending upon which particular is used.

The term "indolinone" is used as that term is commonly understood in the art and includes a large subclass of substituted or unsubstituted compounds that are capable of being synthesized from an aldehyde moiety and an oxindol moiety. Indolinones are a large class of molecules as nearly any aldehyde and nearly any oxindol may be utilized in the reaction.

The term "pharmaceutically acceptable salt" refers to a formulation of a compound that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the compound. Pharmaceutical salts can be obtained by reacting a compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid,

methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, salicylic acid and the like.

In another aspect, the invention features an indolinone compound that modulates the catalytic activity of a protein kinase. Examples of such compounds are listed in Table 1.

The term "modulate" refers to a compound that alters the catalytic activity of a protein kinase. A modulator preferably activates the catalytic activity of a protein kinase, more preferably activates or inhibits the catalytic activity of a protein kinase depending on the concentration of the compound exposed to the protein kinase, or most preferably inhibits the catalytic activity of a protein kinase.

The term "protein kinase" defines a class of proteins that regulate a variety of cellular functions. Protein kinases regulate cellular functions by reversibly phosphorylating protein substrates which thereby changes the conformation of the substrate protein. The conformational change modulates catalytic activity of the substrate or its ability to interact with other binding partners.

The term "catalytic activity", in the context of the invention, defines the rate at which a protein kinase phosphorylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a product as a function of time. Phosphorylation of a substrate occurs at the active-site of a protein kinase. The active-site is

normally a cavity in which the substrate binds to the protein kinase and is phosphorylated.

Inhibitors of protein kinase catalytic activity are known in the art. Small molecule inhibitors typically
5 block the binding of substrates by tightly interacting with the protein kinase active-site. Indolinone compounds, for example, can bind to the active-site of a protein kinase and inhibit the molecule effectively, as measured by inhibition constants on the order of 10^{-6} M.

10 A preferred embodiment of the invention relates to an indolinone compound that inhibits the catalytic activity of a *FLK* protein kinase. The indolinone preferably inhibits the catalytic activity of the *FLK* protein kinase with an IC_{50} less than 50 μ M, more
15 preferably with an IC_{50} less than 5 μ M, and most preferably with an IC_{50} less than 0.5 μ M.

Another preferred embodiment of the invention relates to an indolinone compound that inhibits the catalytic activity of a platelet derived growth factor
20 protein kinase. The indolinone preferably inhibits the catalytic activity of the platelet derived growth factor protein kinase with an IC_{50} less than 50 μ M, more preferably with an IC_{50} less than 5 μ M, and most preferably with an IC_{50} less than 0.5 μ M.

25 The term "*FLK*" refers to a protein kinase that phosphorylates protein substrates on tyrosine residues. The *FLK* protein kinase regulates cellular functions in response to the VEGF growth factor. These cellular functions include, but are not limited to, cellular

proliferation, and in particular, blood vessel proliferation in tissues.

The term "platelet derived growth factor" refers to a protein kinase that phosphorylates substrates on tyrosine residues. The platelet derived growth factor protein kinase regulates cellular functions in response to the PDGF growth factor. These cellular functions include, but are not limited to, cellular proliferation.

The term " IC_{50} ", in the context of the invention, refers to a parameter that describes the concentration of a particular indolinone required to inhibit 50% of the *FLK* protein kinase or platelet derived growth factor protein kinase catalytic activity. The IC_{50} parameter can be measured using an assay described herein and by varying the concentration of a particular indolinone compound.

Another aspect of the invention features a pharmaceutical composition comprising an oxidolinone compound of the invention and a physiologically acceptable carrier or diluent.

The term "pharmaceutical composition" refers to a mixture of an indolinone compound of the invention with other chemical components, such as diluents or carriers. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, oral, injection, aerosol, parenteral, and topical administration. Pharmaceutical compositions can also be obtained by reacting compounds

with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, salicylic acid and the like.

5 The term "physiologically acceptable" defines a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the compound.

10 The term "carrier" defines a chemical compound that facilitates the incorporation of a compound into cells or tissues. For example dimethyl sulfoxide (DMSO) is a commonly utilized carrier as it facilitates the uptake of many organic compounds into the cells or tissues of an organism.

15 The term "diluent" defines chemical compounds diluted in water that will dissolve the compound of interest as well as stabilize the biologically active form of the compound. Salts dissolved in buffered solutions are utilized as diluents in the art. One
20 commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.

25 A final aspect of the invention features a method of preventing or treating an abnormal condition in an organism. The abnormal condition is associated with an aberration in a signal transduction pathway characterized by an interaction between a protein kinase

and a natural binding partner. The method comprises the following steps: (a) administering a compound of the invention to an organism; and (b) promoting or disrupting the abnormal interaction.

5 The term "preventing" refers to a method of barring the organism from acquiring the abnormal condition.

 The term "treating" refers to a method of alleviating or abrogating the abnormal condition in the organism.

10 The term "organism" relates to any living entity comprised of at least one cell. An organism can be as simple as one eukaryotic cell or as complex as a mammal.

 The term "abnormal condition" refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation, or cell survival.

15 Aberrant cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

 Aberrant differentiation conditions include, but are not limited to neurodegenerative disorders, slow wound healing rates, and tissue grafting techniques.

25 Aberrant cell survival conditions relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the

protein kinases could lead to cell immortality or premature cell death.

Cell proliferation, differentiation, and survival are phenomena simply measured by methods in the art.

5 These methods can involve observing the number of cells or the appearance of cells under a microscope with respect to time (days).

The term "administering" relates to a method of incorporating a compound into cells or tissues of an
10 organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism. Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the
15 organism, many techniques exist in the art to administer compounds, including (but not limited to) oral, parenteral, dermal, injection, and aerosol applications. For cells outside of the organism, multiple techniques exist in the art to administer the compounds, including
20 (but not limited to) cell microinjection techniques, transformation techniques, and carrier techniques.

The aberrant condition can also be prevented or treated by administering a group of cells having an aberration in a signal transduction process to an
25 organism. The effect of administering a compound on organism function can then be monitored. The art contains multiple methods of introducing a group of cells to an organism as well as methods of administering a compound to an organism. The organism is preferably a

frog, more preferably a mouse, rat, rabbit, guinea pig, or goat, and most preferably a monkey or ape.

The term "signal transduction pathway" refers to the molecules that propagate an extracellular signal through the cell membrane to become an intracellular signal. This signal can then stimulate a cellular response. The polypeptide molecules involved in signal transduction processes are typically receptor and non-receptor protein kinases, receptor and non-receptor protein phosphatases, nucleotide exchange factors, and transcription factors.

The term "aberration", in conjunction with a signal transduction process, refers to a protein kinase that is over- or under-expressed in an organism, mutated such that its catalytic activity is lower or higher than wild-type protein kinase activity, mutated such that it can no longer interact with a natural binding partner, is no longer modified by another protein kinase or protein phosphatase, or no longer interacts with a natural binding partner.

The term "natural binding partner" refers to a polypeptide that normally binds to the intracellular region of a protein kinase in a cell. These natural binding partners can play a role in propagating a signal in a protein kinase signal transduction process. The natural binding partner can bind to a protein kinase intracellular region with high affinity. High affinity represents an equilibrium binding constant on the order of 10^{-6} M or less. However, a natural binding partner

can also transiently interact with a protein kinase intracellular region and chemically modify it. Protein kinase natural binding partners are chosen from a group consisting of, but not limited to, src homology 2 (SH2) or 3 (SH3) domains, other phosphoryl tyrosine binding (PTB) domains, and other protein kinases or protein phosphatases.

The term "promoting or disrupting the abnormal interaction" refers to a method that can be accomplished by administering a compound of the invention to cells or tissues in an organism. A compound can promote an interaction between a protein kinase and natural binding partners by forming favorable interactions with multiple amino acids at the complex interface. Alternatively, a compound can inhibit an interaction between a protein kinase and natural binding partners by compromising favorable interactions formed between amino acids at the complex interface.

A preferred embodiment of the invention relates to the method of treating an abnormal condition in an organism, where the organism is a mammal.

The term "mammal" refers preferably to such organisms as mice, rats, rabbits, guinea pigs, and goats, more preferably to monkeys and apes, and most preferably to humans.

Another preferred embodiment of the invention relates to a method of treating or preventing an abnormal condition associated with the *FLK* protein kinase.

In yet another preferred embodiment, the invention relates to a method of treating or preventing an abnormal condition associated with the platelet derived growth factor protein kinase.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Table 1 shows illustrative compounds of the invention and the corresponding bioassay which has been used to identify the compound as a tyrosine kinase modulator, serine kinase modulator and/or threonine
10 kinase modulator.

In Table 1, certain abbreviations are used to refer to particular assays as follows:

cprb, cprb-5 - cellular (i.e., whole cells) PDGFR
assay - Example 2(a)(iii)
15 celegf - cellular EGFR assay - Example 2(a)(v)
mflk2 - cellular Flk assay - Example 2(a)(i)
her2 - cellular Her2 assay - Example 2(a)(ii)
celigf1 - cellular IGF1 assay - Example 2(a)(iv)
biokin - biochemical EGFR assay - Example 2(a)(vii)
20 rafmek - biochemical (i.e., lysed cells) Raf assay
- Example 2(a)(vi)

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed in part towards designing compounds that modulate the function of protein kinases.
25 Indolinone compounds that are modified with substituents in the manner set forth herein, effectively modulate the

function of protein kinases. These modulating compounds can therefore be directed towards preventing or treating abnormal conditions in organisms associated with over-active protein kinase function by specifically
5 inhibiting the function of the protein kinase. Alternatively, the modulating compounds can be directed towards preventing or treating abnormal conditions in organisms associated with under-active or non-active protein kinase function by specifically activating the
10 function of the protein kinase.

I. Synthesis of Indolinone Compounds

The indolinone compounds of the invention are synthesized by reacting an aldehyde with an oxindol. Examples of indolinone compounds of the invention are
15 depicted in Table 1. Descriptions of methods for synthesizing indolinone compounds are described in U.S. Application Serial No. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of
20 Disease" by Tang et al. (Lyon & Lyon Docket No. 221/187) (incorporated herein by reference in its entirety, including any drawings) and in the examples described herein. The examples fully describe the solvents, temperatures, separation techniques, and other
25 conditions utilized for the invention. Other methods that may be used or modified by those skilled in the art are described in International Patent Publication number WO 96/22976, published August 1, 1996 by Ballinari et

al., incorporated herein by reference in its entirety,
including any drawings. Descriptions of the methods
used to specifically synthesize the indolinone compounds
of the invention, as shown in Table 1, are disclosed
5 herein.

II. Biological Activity of Indolinone Compounds

Indolinone compounds of the invention can be tested
for their ability to activate or inhibit protein kinases
in biological assays. The methods used to measure
10 indolinone modulation of protein kinase function are
described in U.S. Application Serial No. 08/702,232,
filed August 23, 1996, entitled "Indolinone
Combinatorial Libraries and Related Products and Methods
for the Treatment of Disease" by Tang et al. (Lyon &
15 Lyon Docket No. 221/187) incorporated herein by
reference in its entirety, including any drawings.
Indolinone compounds of the invention were tested for
their ability to inhibit the various protein kinases.
The biological assay and results of these inhibition
20 studies are reported herein.

III. Target Diseases to be Treated by Indolinone Compounds

Protein kinases are essential regulatory molecules
that control a variety of cellular functions. For this
25 reason, any alteration in the function of a protein
kinase can cause an abnormal condition in an organism.

One of the many functions controlled by protein kinases is cell proliferation.

Alterations in the function of a protein kinase that normally regulates cell proliferation can lead to enhanced or decreased cell proliferative conditions evident in certain diseases. Aberrant cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, restenosis, diabetes mellitus, and inflammation.

Fibrotic disorders relate to the abnormal formation of the cellular extracellular matrix. An example of a fibrotic disorder is hepatic cirrhosis. Hepatic cirrhosis is characterized by an increased concentration of extracellular matrix constituents resulting in the formation of a hepatic scar. Hepatic cirrhosis can cause diseases such as cirrhosis of the liver.

Mesangial cell proliferative disorders occur due to the abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies.

Angiogenic and vasculogenic disorders result from excess proliferation of blood vessels. Blood vessel proliferation is necessary in a variety of normal physiological processes such as embryonic development, corpus luteum formation, wound healing and organ

regeneration. However, blood vessel proliferation is also essential in cancer tumor development. Other examples of blood vessel proliferative disorders include arthritis, where new capillary blood vessels invade the joint and destroy cartilage. In addition, blood vessel proliferative diseases include ocular diseases, such as diabetic retinopathy, where new capillaries in the retina invade the vitreous, bleed and cause blindness. Conversely, disorders related to the shrinkage, contraction or closing of blood vessels, such as restenosis, are also implicated in adverse regulation of RPKs or RPPs.

Angiogenic and vasculogenic disorders are closely linked to the *FLK* protein kinase. *FLK*-1 is activated upon binding VEGF, a strong regulator for endothelial cell proliferation as well as normal and pathological angiogenesis. Klagsburn and Soker, 1993, *Current Biology* 3:699-702. Thus, compounds that specifically inhibit the *FLK* protein kinase are potential anti-cancer agents as they may decrease the vasculature that nourishes tumors. These inhibitors will most likely result in minimizing and even obliterating solid tumors. In addition, compounds that specifically inhibit *FLK* will potentially represent a new generation of cancer therapeutics as they will most likely cause few side effects. These potential properties are a significant improvement over the currently utilized cancer therapeutics that cause multiple side effects and deleteriously weaken patients.

In addition to cell proliferation, some RPKs and RPPs regulate the pentultimate cellular functions, cell survival and cell death. Glial derived growth factor (GDNF) activates *c-ret*, for example, by bringing
5 multiple *c-ret* receptors together into close proximity and promoting cross phosphorylation of the intracellular regions. Signal transduction molecules that form a complex with *c-ret* as a result of these phosphoryl moieties, such as *grb-2*, *sos*, *ras*, and *raf*, propagate a
10 signal in the cell that promotes neural survival. Thus, compounds that promote the interactions of these stimulatory molecules of *c-ret* would enhance the activity of *c-ret*. Alternatively, protein phosphatases can remove the phosphoryl moieties placed on the
15 intracellular region of *c-ret* in response to GDNF, and thus inhibit the signaling capability of *c-ret*. Thus compounds that inhibit phosphatases of *c-ret* will enhance the signaling capacity of *c-ret*. In the context of the present invention, the *c-ret* protein kinase could
20 be activated by particular indolinone compounds.

c-ret is implicated in the development and survival of enteric, synaptic, and sensory neurons and neurons of the renal system upon stimulation by GDNF. Lack of function mutations in *c-ret* can lead to
25 Hirschsprung's disease, for example, which manifests itself as a decrease in intestinal tract innervation in patients. Thus, compounds that activate *c-ret* are potential therapeutic agents for the treatment of neurodegenerative disorders, including, but not limited

to, Hirschsprung's disease, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis. Compounds that inhibit c-ret function are possible anti-cancer agents as over-expression of ret in cells is implicated in cancers, such as cancer of the thyroid.

PDGFR kinase inhibitors can be used to treat cancer (glioma et al), arterial restenosis, fibrotic diseases of the lung, kidney and liver, would scarring.

Flk kinase inhibitors can be used to treat endothelial proliferation and diseases including cancer, metastatic disease, rheumatoid arthritis, psoriasis, and ocular diseases including diabetic retinopathies and age-related macular degeneration.

EGFR and HER2 kinase inhibitors can be used to treat cancer (breast, ovarian, squamous cell carcinoma, et al tumors), psoriasis (keratinocyte proliferation).

Raf kinase inhibitors can be used to treat cancer, hyperplasia in arterial restenosis, transplant rejection, inflammation, psoriasis, etc.

IV. Pharmaceutical Compositions and Administration of Indolinone Compounds

Methods of preparing pharmaceutical formulations of the compounds, methods of determining the amounts of compounds to be administered to a patient, and modes of administering compounds to an organism are disclosed U.S. Application Serial No. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of

Disease" by Tang et al. (Lyon & Lyon Docket No. 221/187) incorporated herein by reference in its entirety, including any drawings. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

EXAMPLES

The examples below are not limiting and are merely representative of various aspects and features of the present invention. The examples demonstrate methods of synthesizing indolinone compounds of the invention. The examples also demonstrate the specificity as well as the potency with which these compounds inhibit protein kinase function in cells.

EXAMPLE 1: Synthesis of Indolinone Compounds of the Invention

The compounds of the present invention may be synthesized according to known techniques. The following represent preferred methods for synthesizing the compounds of the claimed invention.

(a) General Syntheses of Indolinone Analogs

The following general methodologies are used to synthesize 3-substituted-2-indolinone compounds of the invention.

(i) Method A

A reaction mixture of the proper oxindole (2-indolinone) (1 equiv.), the appropriate aldehyde (1.2 equiv.), and piperidine (0.1 equiv.) in ethanol (1 - 2 mL / 1 mmol oxindole) is stirred at 90°C for 3 - 5 h. After cooling, the precipitate is filtered, washed with cold ethanol, and dried to yield the target compound.

(ii) Method B

To each well of 96-well reaction plate was dispensed 100 μ L of 0.25 M oxindole in DMSO, 200 μ L of 0.125 M aldehyde in ethanol, 50 μ L of 0.05 M piperidine in ethanol, and 25 μ L of 0.05 M of acetic acid in ethanol. The reaction blocks were then heated to 80°C for 24 hr. Ethanol was then removed under vacuum. The resulting DMSO solution of the reaction residue was then frozen.

EXAMPLE 2: In Vitro RTK Assays

The following in vitro assays may be used to determine the level of activity and effect of the different compounds of the present invention on one or more of the RTKs. Similar assays can be designed along the same lines for any tyrosine kinase using techniques well known in the art.

(a) Enzyme Linked Immunosorbent Assay (ELISA)

Enzyme linked immunosorbent assays (ELISA) may be used to detect and measure the presence of tyrosine kinase activity. The ELISA may be conducted according

to known protocols which are described in, for example, Voller, et al., 1980, "Enzyme-Linked Immunosorbent Assay," In: *Manual of Clinical Immunology*, 2d ed., edited by Rose and Friedman, pp 359-371 Am. Soc. Of Microbiology, Washington, D.C.

The disclosed protocol may be adapted for determining activity with respect to a specific RTK. For example, the preferred protocols for conducting the ELISA experiments for specific RTKs is provided below.

Adaptation of these protocols for determining a compound's activity for other members of the RTK family, as well as non-receptor tyrosine kinases, are within the scope of those in the art.

(i) FLK-1 ELISA

An ELISA assay was conducted to measure the kinase activity of the FLK-1 receptor and more specifically, the inhibition or activation of protein tyrosine kinase activity on the FLK-1 receptor. Specifically, the following assay was conducted to measure kinase activity of the FLK-1 receptor in FLK-1/NIH3T3 cells.

Materials And Methods.

Materials. The following reagents and supplies were used:

- a. Corning 96-well ELISA plates (Corning Catalog No. 25805-96);
- b. Cappel goat anti-rabbit IgG (catalog no. 55641);

- c. PBS (Gibco Catalog No. 450-1300EB);
- d. TBSW Buffer (50 mM Tris (pH 7.2), 150 mM NaCl and 0.1% Tween-20);
- e. Ethanolamine stock (10% ethanolamine (pH 7.0), stored at 4°C);
- f. HNTG buffer (20mM HEPES buffer (pH 7.5), 150mM NaCl, 0.2% Triton X-100, and 10% glycerol);
- g. EDTA (0.5 M (pH 7.0) as a 100X stock);
- h. Sodium ortho vanadate (0.5 M as a 100X stock);
- i. Sodium pyro phosphate (0.2M as a 100X stock);
- j. NUNC 96 well V bottom polypropylene plates (Applied Scientific Catalog No. AS-72092);
- k. NIH3T3 C7#3 Cells (FLK-1 expressing cells);
- l. DMEM with 1X high glucose L Glutamine (catalog No. 11965-050);
- m. FBS, Gibco (catalog no. 16000-028);
- n. L-glutamine, Gibco (catalog no. 25030-016);
- o. VEGF, PeproTech, Inc. (catalog no. 100-20) (kept as 1 µg/100 µl stock in Milli-Q dH₂O and stored at -20°C);
- p. Affinity purified anti-FLK-1 antiserum;
- q. UB40 monoclonal antibody specific for phosphotyrosine (see, Fendley, et al., 1990, *Cancer Research* 50:1550-1558);
- r. EIA grade Goat anti-mouse IgG-POD (BioRad catalog no. 172-1011);
- s. 2,2-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid (ABTS) solution (100mM citric

acid (anhydrous), 250 mM Na_2HPO_4 (pH 4.0), 0.5 mg/ml ABTS (Sigma catalog no. A-1888)), solution should be stored in dark at 4°C until ready for use;

- 5 t. H_2O_2 (30% solution) (Fisher catalog no. H325);
- u. ABTS/ H_2O_2 (15ml ABTS solution, 2 μl H_2O_2)
 prepared 5 minutes before use and left at room
 temperature;
- v. 0.2 M HCl stock in H_2O ;
- 10 w. dimethylsulfoxide (100%) (Sigma Catalog No. D-
 8418); and
- x. Trypsin-EDTA (Gibco BRL Catalog No. 25200-
 049).

Protocol. The following protocol was used for
15 conducting the assay:

- 1. Coat Corning 96-well elisa plates with 1.0 μg
 per well Cappel Anti-rabbit IgG antibody in 0.1M Na_2CO_3
 pH 9.6. Bring final volume to 150 μl per well. Coat
 plates overnight at 4°C. Plates can be kept up to two
20 weeks when stored at 4°C.
- 2. Grow cells in Growth media (DMEM, supplemental
 with 2.0mM L-Glutamine, 10% FBS) in suitable culture
 dishes until confluent at 37°C, 5% CO_2 .
- 3. Harvest cells by trypsinization and seed in
25 Corning 25850 polystyrene 96-well roundbottom cell
 plates, 25,000 cells/well in 200 μl of growth media.
- 4. Grow cells at least one day at 37°C, 5% CO_2 .
- 5. Wash cells with D-PBS 1X.

6. Add 200 μ l/well of starvation media (DMEM, 2.0mM l-Glutamine, 0.1% FBS). Incubate overnight at 37°C, 5% CO₂.
7. Dilute Compounds/Extracts 1:20 in polypropylene 96 well plates using starvation media. Dilute dimethylsulfoxide 1:20 for use in control wells.
8. Remove starvation media from 96 well cell culture plates and add 162 μ l of fresh starvation media to each well.
9. Add 18 μ l of 1:20 diluted Compound/Extract dilution (from step 7) to each well plus the 1:20 dimethylsulfoxide dilution to the control wells (+/- VEGF), for a final dilution of 1:200 after cell stimulation. Final dimethylsulfoxide is 0.5 %.
10. Incubate the plate at 37°C, 5% CO₂ for two hours.
10. Remove unbound antibody from ELISA plates by inverting plate to remove liquid. Wash 3 times with TBSW + 0.5% ethanolamine, pH 7.0. Pat the plate on a paper towel to remove excess liquid and bubbles.
11. Block plates with TBSW + 0.5% Ethanolamine, pH 7.0, 150 μ l per well. Incubate plate thirty minutes while shaking on a microtiter plate shaker.
12. Wash plate 3 times as described in step 10.
13. Add 0.5 μ g/well affinity purified anti-FLU-1 polyclonal rabbit antiserum. Bring final volume to 150 μ l/well with TBSW + 0.5% ethanolamine pH 7.0. Incubate plate for thirty minutes while shaking.
14. Add 180 μ l starvation medium to the cells and stimulate cells with 20 μ l/well 10.0mM sodium ortho

vanadate and 500 ng/ml VEGF (resulting in a final concentration of 1.0mM sodium ortho vanadate and 50ng/ml VEGF per well) for eight minutes at 37°C, 5% CO₂.

Negative control wells receive only starvation medium.

5 15. After eight minutes, media should be removed from the cells and washed one time with 200µl/well PBS.

 16. Lyse cells in 150µl/well HNTG while shaking at room temperature for five minutes. HNTG formulation includes sodium ortho vanadate, sodium pyro phosphate
10 and EDTA.

 17. Wash ELISA plate three times as described in step 10.

 18. Transfer cell lysates from the cell plate to elisa plate and incubate while shaking for two hours.
15 To transfer cell lysate pipette up and down while scrapping the wells.

 19. Wash plate three times as described in step 10.

 20. Incubate ELISA plate with 0.02µg/well UB40 in
20 TBSW + 05% ethanolamine. Bring final volume to 150µl/well. Incubate while shaking for 30 minutes.

 21. Wash plate three times as described in step 10.

 22. Incubate ELISA plate with 1:10,000 diluted EIA
25 grade goat anti-mouse IgG conjugated horseradish peroxidase in TBSW + 0.5% ethanolamine, pH 7.0. Bring final volume to 150µl/well. Incubate while shaking for thirty minutes.

 23. Wash plate as described in step 10.

THIS PAGE BLANK (USPTO)

24. Add 100 μ l of ABTS/H₂O₂ solution to well.

Incubate ten minutes while shaking.

25. Add 100 μ l of 0.2 M HCl for 0.1 M HCl final to
stop the color development reaction. Shake 1 minute at
5 room temperature. Remove bubbles with slow stream of
air and read the ELISA plate in an ELISA plate reader at
410 nm.

(ii) HER-2 ELISA

Assay 1: EGF Receptor-HER2 Chimeric Receptor
10 Assay In Whole Cells. HER2 kinase activity in whole
EGFR-NIH3T3 cells was measured as described below:

Materials and Reagents. The following materials
and reagents were used to conduct the assay:

- 15 a. EGF: stock concentration= 16.5 ILM; EGF 201,
TOYOBO, Co., Ltd. Japan.
- b. 05-101 (UBI) (a monoclonal antibody
recognizing an EGFR extracellular domain).
- c. Anti-phosphotyrosine antibody (anti-Ptyr)
(polyclonal) (see, Fendley, et al., supra).
- 20 d. Detection antibody: Goat anti-rabbit IgG horse
radish peroxidase conjugate, TAGO, Inc.,
Burlingame, CA.
- e. TBST buffer:
- | | | |
|----|------------------|--------|
| 25 | Tris-HCl, pH 7.2 | 50 mM |
| | NaCl | 150 mM |
| | Triton X-100 | 0.1 |
- f. HNTG 5X stock:
- | | | |
|----|----------|--------|
| 30 | HEPES | 0.1 M |
| | NaCl | 0.75 M |
| | Glycerol | 50% |

32

Triton X-100 1.0%

g. ABTS stock:

Citric Acid 100 mM
Na₂HPO₄ 250 mM
HCl, conc. 0.5 pM
ABTS* 0.5mg/ml

* (2,2' -azinobis(3-ethylbenzthiazolinesulfonic acid)). Keep solution in dark at 4°C until use.

h. Stock reagents of:

EDTA 100 mM pH 7.0
Na₃VO₄ 0.5 M
Na₄(P₂O₇) 0.2 M

Procedure. The following protocol was used:

A. Pre-coat ELISA Plate

1. Coat ELISA plates (Corning, 96 well, Cat. #25805-96) with 05-101 antibody at 0.5 g per well in PBS, 100 µl final volume/well, and store overnight at 4°C. Coated plates are good for up to 10 days when stored at 4°C.

2. On day of use, remove coating buffer and replace with 100 µl blocking buffer (5% Carnation Instant Non-Fat Dry Milk in PBS). Incubate the plate, shaking, at room temperature (about 23°C to 25°C) for 30 minutes. Just prior to use, remove blocking buffer and wash plate 4 times with TBST buffer.

B. Seeding Cells

1. An NIH3T3 cell line overexpressing a chimeric receptor containing the EGFR extracellular

domain and extracellular HER2 kinase domain can be used for this assay.

2. Choose dishes having 80-90% confluence for the experiment. Trypsinize cells and stop reaction by adding 10% fetal bovine serum. Suspend cells in DMEM medium (10% CS DMEM medium) and centrifuge once at 1500 rpm, at room temperature for 5 minutes.

3. Resuspend cells in seeding medium (DMEM, 0.5% bovine serum) , and count the cells using trypan blue. Viability above 90% is acceptable. Seed cells in DMEM medium (0.5% bovine serum) at a density of 10,000 cells per well, 100 μ l per well, in a 96 well microtiter plate. Incubate seeded cells in 5% CO₂ at 37°C for about 40 hours.

C. Assay Procedures

1. Check seeded cells for contamination using an inverted microscope. Dilute drug stock (10 mg/ml in DMSO) 1:10 in DMEM medium, then transfer 5 μ l to a TBST well for a final drug dilution of 1:200 and a final DMSO concentration of 1%. Control wells receive DMSO alone. Incubate in 5% CO₂ at 37°C for two hours.

2. Prepare EGF ligand: dilute stock EGF in DMEM so that upon transfer of 10 μ l dilute EGF (1:12 dilution), 100 nM final concentration is attained.

3. Prepare fresh HNTG* sufficient for 100 μ l per well; and place on ice.

HNTG* (10 ml):

HNTG stock	2.0 ml
milli-Q H ₂ O	7.3 ml

EDTA, 100 mM, pH 7.0	0.5 ml
Na ₃ VO ₄ , 0.5 M	0.1 ml
Na ₄ (P ₂ O ₇), 0.2 M	0.1 ml

4. After 120 minutes incubation with drug,
5 add prepared SGF ligand to cells, 10 μ l per well, to a
final concentration of 100 nM. Control wells receive
DMEM alone. Incubate, shaking, at room temperature, for
5 minutes.

5. Remove drug, EGF, and DMEM. Wash cells
10 twice with PBS. Transfer HNTG* to cells, 100 μ l per
well. Place on ice for 5 minutes. Meanwhile, remove
blocking buffer from other ELISA plate and wash with
TBST as described above.

6. With a pipette tip securely fitted to a
15 micropipettor, scrape cells from plate and homogenize
cell material by repeatedly aspirating and dispensing
the HNTG* lysis buffer. Transfer lysate to a coated,
blocked, and washed ELISA plate. Incubate shaking at
room temperature for one hour.

20 7. Remove lysate and wash 4 times with TBST.
Transfer freshly diluted anti-Ptyr antibody to ELISA
plate at 100 μ l per well. Incubate shaking at room
temperature for 30 minutes in the presence of the anti-
Ptyr antiserum (1:3000 dilution in TBST).

25 8. Remove the anti-Ptyr antibody and wash 4
times with TBST. Transfer the freshly diluted TAGO
anti-rabbit IgG antibody to the ELISA plate at 100 μ l
per well. Incubate shaking at room temperature for 30

minutes (anti-rabbit IgG antibody: 1:3000 dilution in TBST).

9. Remove TAGO detection antibody and wash 4 times with TBST. Transfer freshly prepared ABTS/H₂O₂ solution to ELISA plate, 100 μ l per well. Incubate shaking at room temperature for 20 minutes. (ABTS/H₂O₂ solution: 1.0 μ l 30% H₂O₂ in 10 ml ABTS stock).

10. Stop reaction by adding 50 μ l 5N H₂SO₄ (optional), and determine O.D. at 410 nm.

11. The maximal phosphotyrosine signal is determined by subtracting the value of the negative controls from the positive controls. The percent inhibition of phosphotyrosine content for extract-containing wells is then calculated, after subtraction of the negative controls.

Assay 2: HER-2-BT474 ELISA. A second assay may be conducted to measure whole cell HER2 activity. Such assay may be conducted as follows:

Materials And Reagents. The following materials and reagents were used:

- a. BT-474 (ATCC HBT20), a human breast tumor cell line which expresses high levels of HER2 kinase.
- b. Growth media comprising RPMI + 10% FBS + GMS-G (Gibco supplement) + glutamine for use in growing BT-474 in an incubator with 5% CO₂ at 37°C.
- c. A monoclonal anti-HER2 antibody.
- d. D-PBS:

KH_2HPO_4 0.20 g/l 10 (GIBCO, 310-4190AJ)
 K_2HPO_4 2.16 g/l
KCl 0.20 g/l
NaCl 8.00 g/l (pH 7.2)

5 e. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk).

f. TBST buffer:

10 Tris-HCl 50 mM
NaCl 150 mM (pH 7.2, HCl 10 N)
Triton X-100 0.1%

wherein stock solution of TES (10X) is prepared, and Triton X-100 is added to the buffer during dilution.

g. HNTG buffer (5x):

15 HEPES 0.1 M
NaCl 750 mM (pH 7.2 (HCl, 1 N)
Glycerol 50%
Triton X-100 1.0%

20 Stock solution (5x) is prepared and kept in 4°C.

h. EDTA-HCl: 0.5 M pH 7.0 (10 N HCl) as 500X stock.

i. Na_3VO_4 : 0.5 M as 100X stock is kept at -80°C as aliquots.

25 j. $\text{Na}_4(\text{P}_2\text{O}_7)$: 0.2 M as 100X stock.

k. Polyclonal antiserum anti-phosphotyrosine.

30 l. Goat anti-rabbit IgG, horseradish peroxidase (POD) conjugate (detection antibody), Tago (Cat. No. 4520; Lot No. 1802): Tago, Inc., Burlingame, CA.

m. ABTS solution:

Citric acid	100 mM
Na ₂ HPO ₄	250 mM (pH 4.0, 1 N HCl)
ABTS	0.5 mg/ml

5 wherein ABTS is 2,2'-azinobis(3-ethylbenzthiazoline sulfonic acid). For this assay, the ABTS solution should be kept in the dark at 4°C. The solution should be discarded when it turns green.

10 n. Hydrogen peroxide: 30% solution is kept in dark and 4°C.

Procedure. All the following steps are at room temperature and aseptically, unless stated otherwise. All ELISA plate washing is by rinsing with distilled water three times and once with TBST.

15 A. Cell Seeding

 1. Grow BT474 cells in tissue culture dishes (Corning 25020-100) to 80-90% confluence and collect using Trypsin-EDTA (0.25%, GIBCO).

 2. Resuspend the cells in fresh medium and
20 transfer to 96-well tissue culture plates (Corning, 25806-96) at about 25,000-50,000 cells/well (100 µl/well) . Incubate the cells in 5% CO₂ at 37°C overnight.

 B. ELISA Plate Coating and Blocking

25 1. Coat the ELISA plate (Corning 25805-96) with anti HER2 antibody at 0.5 µg/well in 150 µl PBS overnight at 4°C, and seal with parafilm. The antibody coated plates can be used up to 2 weeks, when stored at 4°C.

30 2. On the day of use, remove the coating solution, replace with 200 µl of Blocking Buffer, shake

the plate, and then remove the blocking buffer and wash the plate just before adding lysate.

C. Assay Procedures

1. TBST the drugs in serum-free condition.
5 Before adding drugs, the old media is replaced with serum-free RPMI (90 μ l/well)

2. Dilute drug stock (in 100% DMSO) 1:10 with RPMI, and transfer 10 μ l/well of this solution to the cells to achieve a final drug DMSO concentration at
10 1%. Incubate the cells in 5% CO₂ at 37°C.

3. Prepare fresh cell lysis buffer (HNTG*)
5xHNTG 2 ml
EDTA 0.2 ml
Na₃VO₄ 0.1 ml
15 Na₄P₂O₇ 0.1 ml
H₂O 7.3 ml

4. After drug preincubation for two hours remove all the solution from the plate, transfer HNTG* (100 μ l/well) to the cells, and shake for 10 minutes.

20 5. Use a 12-channel pipette to scrape the cells from the plate, and homogenize the lysate by repeat aspiration and dispensing. Transfer all the lysate to the ELISA plate and shake for 1 hour.

6. Remove the lysate, wash the plate, add
25 anti-pTyr (1:3,000 with TBST) 100 μ l/well, and shake for 30 minutes.

7. Remove anti-pTyr, wash the plate, add goat anti-rabbit IgG conjugated antibody (1:5,000 with TBST) 100 μ l/well, and shake for 30 minutes.

8. Remove anti-rabbit IgG antibody, wash the plate, and add fresh ABTS/H₂O₂ (1.2 μ l H₂O₂ to 10 ml ABTS) 100 l/well to the plate to start color development, which usually takes 20 minutes.

5 9. Measure OD 410 nM, Dynatec MR5000.

(iii) PDGF-R ELISA

All cell culture media, glutamine, and fetal bovine serum were purchased from Gibco Life Technologies (Grand Island, NY) unless otherwise specified. All
10 cells were grown in a humid atmosphere of 90-95% air and 5-10% CO₂ at 37°C. All cell lines were routinely subcultured twice a week and were negative for mycoplasma as determined by the Mycotect method (Gibco).

For ELISA assays, cells (U1242, obtained from
15 Joseph Schlessinger, NYU) were grown to 80-90% confluency in growth medium (MEM with 10% FBS, NEAA, 1 mM NaPyr and 2 mM GLN) and seeded in 96-well tissue culture plates in 0.5% serum at 25,000 to 30,000 cells per well. After overnight incubation in 0.5% serum-
20 containing medium, cells were changed to serum-free medium and treated with test compound for 2 hr in a 5% CO₂, 37°C incubator. Cells were then stimulated with ligand for 5-10 minute followed by lysis with HNTG (20 mM Hepes, 150 mM NaCl, 10% glycerol, 5 mM EDTA, 5 mM
25 Na₃VO₄, 0.2% Triton X-100, and 2 mM NaPyr). Cell lysates (0.5 mg/well in PBS) were transferred to ELISA plates previously coated with receptor-specific antibody and which had been blocked with 5% milk in TBST (50 mM Tris-

HCl pH 7.2, 150 mM NaCl and 0.1% Triton X-100) at room temperature for 30 min. Lysates were incubated with shaking for 1 hour at room temperature. The plates were washed with TBST four times and then incubated with polyclonal anti-phosphotyrosine antibody at room temperature for 30 minutes. Excess anti-phosphotyrosine antibody was removed by rinsing the plate with TBST four times. Goat anti-rabbit IgG antibody was added to the ELISA plate for 30 min at room temperature followed by rinsing with TBST four more times. ABTS (100 mM citric acid, 250 mM Na₂HPO₄ and 0.5 mg/mL 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)) plus H₂O₂ (1.2 mL 30% H₂O₂ to 10 ml ABTS) was added to the ELISA plates to start color development. Absorbance at 410 nm with a reference wavelength of 630 nm was recorded about 15 to 30 min after ABTS addition.

(iv) IGF-I ELISA

The following protocol may be used to measure phosphotyrosine level on IGF-I receptor, which indicates IGF-I receptor tyrosine kinase activity.

Materials And Reagents. The following materials and reagents were used:

- a. The cell line used in this assay is 3T3/IGF-1R, a cell line which overexpresses IGF-1 receptor.
- b. NIH3T3/IGF-1R is grown in an incubator with 5% CO₂ at 37°C. The growth media is DMEM + 10% FBS (heat inactivated) + 2mM L-glutamine.

- c. Anti-IGF-1R antibody named 17-69 is purified and used.
- d. D-PBS:
- | | | |
|---|---------------------------------|-------------------|
| 5 | KH ₂ PO ₄ | 0.20 g/l |
| | K ₂ HPO ₄ | 2.16 g/l |
| | KCl | 0.20 g/l |
| | NaCl | 8.00 g/l (pH 7.2) |
- e. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk).
- 10 f. TBST buffer:
- | | | |
|--|--------------|------------------------|
| | Tris-HCl | 50 mM |
| | NaCl | 150mM (pH 7.2/HCl 10N) |
| | Triton X-100 | 0.1% |
- 15 Stock solution of TBS (10X) is prepared, and Triton X-100 is added to the buffer during dilution.
- g. HNTG buffer:
- | | | |
|----|--------------|------------------------|
| 20 | HEPES | 20 mM |
| | NaCl | 150 mM (pH 7.2/HCl 1N) |
| | Glycerol | 10% |
| | Triton X-100 | 0.2% |
- Stock solution (5X) is prepared and kept at 4°C.
- h. EDTA/HCl: 0.5 M pH 7.0 (NaOH) as 100X stock.
- 25 i. Na₃VO₄: 0.5 M as 100X stock and aliquots are kept in -80°C.
- j. Na₄P₂O₇: 0.2 M as 100X stock.
- k. Insulin-like growth factor-1 from Promega (Cat# G5111).

1. Polyclonal antiserum anti-phosphotyrosine:
rabbit sera or UB40 monoclonal antibody
specific for phosphotyrosine.
- 5 m. Goat anti-rabbit IgG, POD conjugate (detection
antibody), Tago (Cat. No. 4520, Lot No. 1802):
Tago, Inc., Burlingame, CA.
- n. ABTS (2,2'-azinobis(3-
ethylbenzthiazolinesulfonic acid)) solution:
- | | | |
|----|----------------------------------|-------------------------|
| 10 | Citric acid | 100 mM |
| | Na ₂ HPO ₄ | 250 mM (pH 4.0/1 N HCl) |
| | ABTS | 0.5 mg/ml |
- ABTS solution should be kept in dark
and 4°C. The solution should be
discarded when it turns green.
- 15 o. Hydrogen Peroxide: 30% solution is kept in the
dark and at 4°C.

Procedure. All the following steps are conducted
at room temperature unless it is specifically indicated.
All ELISA plate washings are performed by rinsing the
20 plate with tap water three times, followed by one TBST
rinse. Pat plate dry with paper towels.

A. Cell Seeding:

1. The cells, grown in tissue culture dish
(Corning 25020-100) to 80-90% confluence, are harvested
25 with Trypsin-EDTA (0.25%, 0.5 ml/D-100, GIBCO).
2. Resuspend the cells in fresh DMEM + 10%
FBS + 2mM L-Glutamine, and transfer to 96 - well tissue
culture plate (Corning, 25806-96) at 20,000 cells/well
(100 µl/well). Incubate for 1 day then replace medium
30 to serum-free medium (90/µl) and incubate in 5% CO₂ and
37°C overnight.

B. ELISA Plate Coating and Blocking:

1. Coat the ELISA plate (Corning 25805-96) with Anti-IGF-1R Antibody at 0.5 μ g/well in 100 μ l PBS at least 2 hours.

5 2. Remove the coating solution, and replace with 100 μ l Blocking Buffer, and shake for 30 minutes. Remove the blocking buffer and wash the plate just before adding lysate.

C. Assay Procedures:

10 1. The drugs are tested in serum-free condition.

2. Dilute drug stock (in 100% DMSO) 1:10 with DMEM in 96-well poly-propylene plate, and transfer 10 μ l/well of this solution to the cells to achieve
15 final drug dilution 1:100, and final DMSO concentration of 1.0%. Incubate the cells in 5% CO₂ at 37°C for 2 hours.

3. Prepare fresh cell lysis buffer (HNTG*)

	HNTG	2 ml
20	EDTA	0.1 ml
	Na ₃ VO ₄	0.1 ml
	Na ₄ (P ₂ O ₇)	0.1 ml
	H ₂ O	7.3 ml

4. After drug incubation for two hours,
25 transfer 10 μ l/well of 200nM IGF-1 Ligand in PBS to the cells (Final Conc. = 20 nM), and incubate at 5% CO₂ at 37°C for 10 minutes.

5. Remove media and add 100 μ l/well HNTG* and shake for 10 minutes. Look at cells under microscope to see if they are adequately lysed.

6. Use a 12-channel pipette to scrape the cells from the plate, and homogenize the lysate by repeat aspiration and dispense. Transfer all the lysate to the antibody coated ELISA plate, and shake for 1 hour.

7. Remove the lysate, wash the plate, transfer anti-pTyr (1:3,000 with TBST) 100 μ l/well, and shake for 30 minutes.

8. Remove anti-pTyr, wash the plate, transfer Tago (1:3,000 with TBST) 100 μ l/well, and shake for 30 minutes.

9. Remove detection antibody, wash the plate, and transfer fresh ABTS/H₂O₂ (1.2 μ l H₂O₂ to 10 ml ABTS) 100 μ l/well to the plate to start color development.

10. Measure OD in Dynatec MR5000, which is connected to Ingres.

(v) EGF Receptor ELISA

EGF Receptor kinase activity (EGFR-NIH3T3 assay) in whole cells was measured as described below:

Materials and Reagents. The following materials and reagents were used

- a. EGF Ligand: stock concentration = 16.5 μ M; EGF 201, TOYOCO, Co., Ltd. Japan.
- b. 05-101 (UBI) (a monoclonal antibody recognizing an EGFR extracellular domain).

45

- c. Anti-phosphotyrosine antibody (anti-Ptyr)
(polyclonal).
- d. Detection antibody: Goat anti-rabbit IgG horse
radish peroxidase conjugate, TAGO, Inc.,
Burlingame, CA.
- e. TBST buffer:
- | | |
|-----------------|--------|
| Tris-HCl, pH 7. | 50 mM |
| NaCl | 150 mM |
| Triton X-100 | 0.1 |
- f. HNTG 5X stock:
- | | |
|--------------|--------|
| HEPES | 0.1 M |
| NaCl | 0.75 M |
| Glycerol | 50 |
| Triton X-100 | 1.0% |
- g. ABTS stock:
- | | |
|----------------------------------|-----------|
| Citric Acid | 100 mM |
| Na ₂ HPO ₄ | 250 mM |
| HCl, conc. | 4.0 pH |
| ABTS* | 0.5 mg/ml |
- Keep solution in dark at 4°C until used.
- h. Stock reagents of:
- | |
|--|
| EDTA 100 mM pH 7.0 |
| Na ₃ VO ₄ 0.5 M |
| Na ₄ (P ₂ O ₇) 0.2 M |

Procedure. The following protocol was used:

A. Pre-coat ELISA Plate

1. Coat ELISA plates (Corning, 96 well, Cat. #25805-96) with 05-101 antibody at 0.5 µg per well in PBS, 150 µl final volume/well, and store overnight at

4°C. Coated plates are good for up to 10 days when stored at 4°C.

2. On day of use, remove coating buffer and replace with blocking buffer (5% Carnation Instant Non-Fat Dry Milk in PBS). Incubate the plate, shaking, at room temperature (about 23°C to 25°C) for 30 minutes. Just prior to use, remove blocking buffer and wash plate 4 times with TBST buffer.

B. Seeding Cells

1. NIH 3T3/C7 cell line (Honegger, et al., Cell 51:199-209, 1987) can be use for this assay.

2. Choose dishes having 80-90% confluence for the experiment. Trypsinize cells and stop reaction by adding 10% CS DMEM medium. Suspend cells in DMEM medium (10% CS DMEM medium) and centrifuge once at 1000 rpm, and once at room temperature for 5 minutes.

3. Resuspend cells in seeding medium (DMEM, 0.5% bovine serum), and count the cells using trypan blue. Viability above 90% is acceptable. Seed cells in DMEM medium (0.5% bovine serum) at a density of 10,000 cells per well, 100 μ l per well, in a 96 well microtiter plate. Incubate seeded cells in 5% CO₂ at 37°C for about 40 hours.

C. Assay Procedures.

1. Check seeded cells for contamination using an inverted microscope. Dilute drug stock (10 mg/ml in DMSO) 1:10 in DMEM medium, then transfer 5 μ l to a test well for a final drug dilution of 1:200 and a

final DMSO concentration of 1%. Control wells receive DMSO alone. Incubate in 5% CO₂ at 37°C for one hour.

2. Prepare EGF ligand: dilute stock EGF in DMEM so that upon transfer of 10 µl dilute EGF (1:12 dilution), 25 nM final concentration is attained.

3. Prepare fresh 10 ml HNTG* sufficient for 100 µl per well wherein HNTG* comprises: HNTG stock (2.0 ml), milli-Q H₂O (7.3 ml), EDTA, 100 mM, pH 7.0 (0.5 ml), Na₃VO₄ 0.5 M (0.1 ml) and Na₄ (P₂O₇), 0.2 M (0.1 ml).

4. Place on ice.

5. After two hours incubation with drug, add prepared EGF ligand to cells, 10 µl per well, to yield a final concentration of 25 nM. Control wells receive DMEM alone. Incubate, shaking, at room temperature, for 5 minutes.

6. Remove drug, EGF, and DMEM. Wash cells twice with PBS. Transfer HNTG* to cells, 100 µl per well. Place on ice for 5 minutes. Meanwhile, remove blocking buffer from other ELISA plate and wash with TBST as described above.

7. With a pipette tip securely fitted to a micropipettor, scrape cells from plate and homogenize cell material by repeatedly aspirating and dispensing the HNTG* lysis buffer. Transfer lysate to a coated, blocked, and washed ELISA plate. Incubate shaking at room temperature for one hour.

8. Remove lysate and wash 4 times with TBST. Transfer freshly diluted anti-Ptyr antibody to ELISA plate at 100 µl per well. Incubate shaking at room

temperature for 30 minutes in the presence of the anti-Ptyr antiserum (1:3000 dilution in TBST).

9. Remove the anti-Ptyr antibody and wash 4 times with TBST. Transfer the freshly diluted TAGO 30 anti-rabbit IgG antibody to the ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes (anti-rabbit IgG antibody: 1:3000 dilution in TBST).

10. Remove detection antibody and wash 4 times with TBST. Transfer freshly prepared ABTS/H₂O₂ solution to ELISA plate, 100 μ l per well. Incubate at room temperature for 20 minutes. ABTS/H₂O₂ solution: 1.2 μ l 30% H₂O₂ in 10 ml ABTS stock.

11. Stop reaction by adding 50 μ l 5N H₂SO₄ (optional), and determine O.D. at 410 nm.

12. The maximal phosphotyrosine signal is determined by subtracting the value of the negative controls from the positive controls. The percent inhibition of phosphotyrosine content for extract-containing wells is then calculated, after subtraction of the negative controls.

(vi) Cellular Insulin Receptor ELISA

The following protocol was used to determine whether the compounds of the present invention possessed insulin receptor tyrosine kinase activity.

Materials And Reagents. The following materials and reagents were used to measure phosphotyrosine levels

on the insulin receptor (indicating insulin receptor tyrosine kinase activity):

1. The preferred cell line was an NIH3T3 cell line (ATCC No. 1658) which overexpresses Insulin Receptor (H25 cells);
2. H25 cells are grown in an incubator with 5% CO₂ at 37°C. The growth media is DMEM + 10% FBS (heat inactivated) + 2mm L-Glutamine;
3. For ELISA plate coating, the monoclonal anti-IR antibody named BBE is purified and used;
4. D-PBS, comprising:

KH ₂ PO ₄	0.20 g/l (GIBCO, 310-4190AJ)
K ₂ HPO ₄	2.16 g/l
KCl	0.20 g/l
NaCl	8.00 g/l (pH 7.2);
5. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk);
6. TBST buffer, comprising:

Tris-HCl	50mM
NaCl	150mM pH 7.2 (HCl, 1 N)
Triton X-100	0.1%
- Note: Stock solution of TBS (10X) is prepared, and Triton X-100 is added to the buffer during dilution;
7. HNTG buffer, comprising:

HEPES	20mM
NaCl	150mM pH 7.2 (HCl, 1 N)
Glycerol	10%
Triton X-100	0.2%

Note: Stock solution (5X) is prepared and kept at 4°C;

8. EDTA.HCl: 0.5 M pH 7.0 (NaOH) as 100X stock;
9. Na_3VO_4 : 0.5 M as 100X stock and aliquots are kept in -80°C ;
10. $\text{Na}_4\text{P}_2\text{O}_7$: 0.2 M as 100X stock;
- 5 11. Insulin from GIBCO BRL (Cat# 18125039);
12. Polyclonal antiserum Anti-phosphotyrosine: rabbit sera or UB40 monoclonal antibody specific for phosphotyrosine.
13. Detection antibody, preferably goat anti-rabbit IgG, POD conjugate, Tago (Cat. No. 4520: Lot No. 1802): Tago, Inc., Burlingame, CA;
- 10 14. ABTS solution, comprising:
- | | |
|---------------------------|-------------------------|
| Citric acid | 100 mM |
| Na_2HPO_4 | 250 mM pH 4.0 (1 N HCl) |
| 15 ABTS | 0.5 mg/ml |
- wherein ABTS is 2,2'-azinobis (3-ethylbenzothiazoline sulfonic acid) and stored in the dark at 4°C and discarded when it turns green;
- 15 15. Hydrogen Peroxide: 30% solution is kept in the dark and at 40°C .
- 20 **Protocol.** All the following steps are conducted at room temperature unless it is specifically indicated. All ELISA plate washings are performed by rinsing the plate with tap water three times, followed by one TBST
- 25 rinse. All plates were tapped dry with paper towels prior to use.
- A. Cell Seeding:
1. The cells were grown in tissue culture dish (10 cm, Corning 25020-100) to 80-90% confluence and

harvested with Trypsin-EDTA (0.25%, 0.5 ml/D-100, GIBCO);

2. Resuspend the cells in fresh DMEM + 10% FBS + 2mM L-Glutamine, and transfer to 96 - well tissue culture plate (Corning, 25806-96) at 20,000 cells/well (100 μ l/well). The cells are then incubated for 1 day. Following such incubation, 0.01% serum medium (90/ μ l) replaces the old media and the cells incubate in 5% CO₂ and 37°C overnight.

10 B. ELISA Plate Coating and Blocking:

1. Coat the ELISA plate (Corning 25805-96) with Anti-IR Antibody at 0.5 μ g/well in 100 μ l PBS at least 2 hours.

2. Remove the coating solution, and replace with 100 μ l blocking Buffer, and shake for 30 minutes. Remove the blocking buffer and wash the plate just before adding lysate.

C. Assay Procedures

1. The drugs are tested in serum-free condition.

2. Dilute drug stock (in 100% DMSO) 1:10 with DMEM in 96-well poly-propylene plate, and transfer 10 μ l/well of this solution to the cells to achieve final drug dilution 1:100, and final DMSO concentration of 1.0%. Incubate the cells in 5% CO₂ at 37°C for 2 hours.

3. Prepare fresh cells lysis buffer (HNTG*)

HNTG (5x)	2 ml
EDTA	0.1 ml

Na_3VO_4	0.1 ml
$\text{Na}_4\text{P}_2\text{O}_7$	0.1 ml
H_2O	7.3 ml
HNTG*	10 ml

- 5 4. After drug incubation for two hours,
transfer 10 μl /well of 1 μM insulin in PBS to the cells
(Final concentration = 100 nM), and incubate at 5% CO_2 at
37°C for 10 minutes.
- 10 5. Remove media and add 100 μl /well HNTG*
and shake for 10 minutes. Look at cells under
microscope to see if they are adequately lysed.
- 15 6. Using a 12-channel pipette, scrape the
cells from the plate, and homogenize the lysate by
repeat aspiration and dispense. Transfer all the lysate
to the antibody coated ELISA plate, and shake for 1
hour.
- 20 7. Remove the lysate, wash the plate,
transfer anti-pTyr (1:3,000 with TBST) 100 μl /well, and
shake for 30 minutes.
- 25 8. Remove anti-pTyr, wash the plate,
transfer Tago (1:3,000 with TBST) 100 μl /well, and shake
for 30 minutes.
9. Remove detection antibody, wash the
plate, and transfer fresh ABTS/ H_2O_2 (1.2 μl H_2O_2 to 10 ml
ABTS) 100 μl /well to the plate to start color
development.
10. Measure OD in Dynatec MR5000, which is
connected to Ingres. All following steps should follow
Ingres instruction.

5. Blocking Buffer

Formulation: 5% Carnation Instant Milk in
PBS

6. A431 cell lysate

5 A431 cells are available from a variety of
commercial sources and may be used lysed using
conventional methods known to those skilled in the art
or as described for lysis of the 3T3 cells in the EGF
cellular assay described herein. -80 C, 1 ml aliquots

10 7. TBS Buffer

Formulation: 50 mM Tris pH 7.2
150 mM NaCl

8. TBS + 10% DMSO

Formulation: 10% DMSO in TBS Buffer
15 (DMSO from Sigma, Catalog # D-2650)

9. ATP/MnCl₂ phosphorylation mix

Formulation: 0.03 mM ATP
(Adenosine-5'-triphosphate, Sigma Catalog
#A-5394)

20 50 mM MnCl₂

Make fresh in autoclaved Milli-Q H₂O
immediately before use

Keep on ice until use

10. NUNC 96-well V bottom polypropylene plates

25 Applied Scientific Catalog # AS-72092

11. EDTA

Formulation: 200 mM EDTA pH 8.0

12. Rabbit polyclonal anti-phosphotyrosine serum
or UB40 monoclonal antibody specific for phosphotyrosine

55

- 80 C, 1 ml aliquots

Thaw 1 ml vial and aliquot in smaller volumes
to store at - 80 C

Antiserum is stable for weeks when thawed and
5 stored at 4 C

13. Goat anti-rabbit IgG peroxidase conjugate
Biosource Catalog # ALI0404

14. ABTS Solution

Formulation: 100 mM Citric Acid (anhydrous)
10 250 mM Na₂HPO₄ pH 4.0
0.5 mg/ml ABTS

(2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)
(Sigma Catalog # A-1888)

15 Keep solution in dark at 4 C until ready to
use

15. Hydrogen peroxide 30% solution

Fisher Catalog # H325

Store in the dark at 4 C until ready to use

20 16. ABTS/H₂O₂

Formulation: 15 mls ABTS solution

2 ul H₂O₂

Prepare 5 minutes before use and room
temperature

25 17. 0.2 M HCL stock in H₂O

Procedure.

1. Coat Corning 96-well elisa plates with 0.5 ug
per well 05-101 antibody.

56

Bring final volume to 100 ul per well with
PBS.

Coat plates overnight at 4 C.

2. Remove unbound 05-101 from wells by inverting
5 plate to remove liquid.

Wash 1x with distilled H₂O by filling wells
Pat the plate on a paper towel to remove
excess liquid.

3. Block plates with 5% milk in PBS.
10 150 ul per well.

Incubate plate 30 minutes while shaking on a
microtiter plate shaker.

4. Wash plate 3x with dionized water, then once
with TBST

- 15 5. Add 7 ug A431 cell lysate per well (EGFR
source).

Add PBS to final volume of 100 ul per well

Incubate 30 minutes while shaking.

6. Wash as described in step 4.

- 20 7. At this point, drugs or extracts are added to
the wells.

Dilute drugs/extracts 1:100 (unless specified
otherwise) in TBS + 10% DMSO in 96-well polypropylene
plates.

- 25 Add 120 ul TBS to ELISA plate containing
captured EGFR.

Add 13.5 ul diluted drugs/extracts to ELISA
plate.

57

To control wells (wells which do not receive any drug) add 135 ul TBS
+ 1% DMSO.

Incubate plate 30 minutes while shaking.

- 5 8. Add 15 ul of 0.03 mM ATP + 50 mM MnCl₂
phosphorylation mix directly to all wells except
negative control well which does not receive ATP/MnCl₂
(see diagram).

(150 ul final volume in well with 3 uM ATP/5
10 mM MnCl₂ final concentration in well.)

Incubate 5 minutes while shaking vigorously.

*NOTE: It is critical that ATP/MnCl₂
phosphorylates the receptor for 5 minutes
only. It is best to add the ATP/MnCl₂ with an 12
15 channel pipettor 1 row at a time leaving 20 seconds
between each row so that the reaction may be stopped
with EDTA exactly 5 minutes later (this depends on the
number of plates being phosphorylated in one batch).
Shake between each addition.

- 20 9. After 5 minutes, to stop reaction, add 16.5 ul
of 200 mM EDTA pH 8.0 for 20 mM final in well, shaking
continuously between each addition. This is done using
the same timing method as above. After last row has
received EDTA, shake plate an additional minute.

- 25 10. Wash 4x with deionized water, twice with TBST.
11. Add rabbit polyclonal anti-phosphotyrosine
serum.

Dilute 1:3000 in TBST.

Add 100 ul per well.

Incubate 30-45 minutes while shaking.

12. Wash as described above in step 4.

13. Add BioSource anti-rabbit peroxidase conjugate antibody.

5 Dilute 1:2000 in TBST.

Add 100 ul per well.

Incubate 30 minutes while shaking.

14. Wash as described in step 4.

15. Add 100 ul of ABTS/H₂O₂ solution to well.

10 Incubate 5 to 10 minutes while shaking.

Remove bubbles

16. If necessary stop reaction with the addition of 100ul of 0.2M HCl per well

17. Read assay on Dynatech MR7000 elisa reader.

15 Test Filter: 410 nM

Reference Filter: 630 nM

(b) Cell Growth Assays

The following assays may be conducted to measure the effect of the claimed compounds upon cell growth as a result of the compound's interaction with one or more RTKs. Unless otherwise specified, the following assays may be generally applied to measure the activity of a compound against any particular RTK. To the extent that an assay, set forth below, refers to a specific RTK, one skilled in the art would be able to adapt the disclosed protocol for use to measure the activity of a second RTK.

(i) Soft Agar Assay

The soft agar assay may be used to measure the effects of substances on cell growth. Unless otherwise stated the soft agar assays were carried out as follows:

5 **Material And Reagents.** The following materials and reagents were used:

- a. A water bath set at 39°C and another water bath at 37°C.
- 10 b. 2X assay medium is comprised of 2X Dulbecco's 5Modified Eagle's Medium (DMEM) (Gibco Cat. # CA400-4ANO3) supplemented by the following:
 - 20% Fetal Bovine Serum (FBS) 2 mM sodium pyruvate 4 mM glutamine amine; and
 - 15 • 20 mM HEPES Non-essential Amino Acids (1:50 from 100x stock).
- 20 c. 1X assay medium made of 1X DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM glutamine, 10 mM HEPES, non-essential amino acid (1:100 from 100x stock).
- 25 d. 1.6% SeaPlaque Agarose in autoclave bottle.
- e. Sterile 35 mm Corning plates (FMC Bioproducts Cat. #50102).
- f. Sterile 5 ml glass pipets (individually wrapped).
- g. Sterile 15 ml and 50 ml conical centrifuge tubes.
- h. Pipets and sterile tips.
- i. Sterile microcentrifuge tubes.
- 30 j. Cells in T75 flasks: SKOV-3 (ATCC HTB77).

k. 0.25% Trypsin solution (Gibco #25200-015).

Procedure. The following procedure was used to conduct the soft agar assay:

A. Procedure for making the base layer

- 5 1. Have all the media warmed up in the 37°C water bath.
2. To make 1X of assay medium + 0.8% agar: make a 1:2 (vol:vol) dilution of melted agar (cooled to 39°C), with 2X assay medium.
- 10 3. Keep all media with agar warm in the 39°C water bath when not in use.
4. Dispense 1 ml of 1X assay medium + 0.8% agar into dishes and gently swirl plate to form a uniform base layer. Bubbles should be avoided.
- 15 5. Refrigerate base layers to solidify (about 20 minutes). Base layers can be stored overnight in the refrigerator.

B. Procedure for collecting cells

- 20 1. Take out one flask per cell line from the incubator; aspirate off medium; wash once with PBS and aspirate off; add 3 ml of trypsin solution.
2. After all cells dissociate from the flask, add 3 ml of 1X assay media to inhibit trypsin activity. Pipet the cells up and down, then transfer
- 25 the suspension into a 15ml tube.
3. Determine the concentration of cells using a Coulter counter, and the viability by trypan blue exclusion.

4. Take out the appropriate volume needed to seed 3300 viable cells per plate and dilute it to 1.5 ml with 1X assay medium.

5 C. Procedure for making the upper 0.4% agarose layer:

1. Add TBST compounds at twice the desired final assay concentration; + 1.5 ml of cell suspension in 1X assay medium 10% FBS; + 1.5 ml of 1X assay medium + 0.8% agarose*: Total = 3.0 ml 1X media 10% FBS + 0.4% agarose with 3300 viable cells/ml, with and without TBST compounds.

*(Made by 1:2 dilution of 2X media with 1.6% agar 30 for the base layer procedure above.)

15 2. Plate 1 ml of the Assay Mix onto the 1 ml base layer. The duplicates are plated from the 3 ml volume.

3. Incubate the dishes for 2-3 weeks in a 100% humidified, 10% CO₂ incubator.

20 4. Colonies that are 60 microns and larger are scored positive.

(ii) **Sulforhodamine B (SRB) Growth Assays**

The SRB assays may be used to measure the effects of substances or cell growth. The assays are carried out as follows:

25 **Assay 1: 3T3/E/H+TGF- α (T) Cell Growth SRB Assay**

Materials:

96-well flat bottom sterile plates

96-well round bottom sterile plates

sterile 25 ml or 100 ml reservoir
pipets, multi-channel pipetman
sterile pipet tips
sterile 15 ml and 50 ml tubes

5 Reagents:

0.4% SRB in 1% acetic acid

10 mM Tris base

10% TCA

1% acetic acid

10 sterile DMSO (Sigma)

compound in DMSO (100 mM or less stock solution)

25% Trypsin-EDTA in Cell Dissociation Solution (Sigma)

Cell line and growth medium:

15 3T3/E/H+TGF- α (T) (NIH 3T3 clone 7 cells expressing EGF-
R/HER2 chimera and TGF- α , tumor-derived autocrine loop
cells)

2% calf serum/DMEM + 2 mM glutamine

Protocol:

Day 0: Cell Plating:

20 This part of assay is carried out in a laminar flow
hood.

1. Trypsinize cells as usual. Transfer 100 μ l of
cell suspension to 10 ml of isotone. Count cells with
the Coulter Counter.

2. Dilute cells in growth medium to 60,000 cells/ml. Transfer 100 μ l of cells to each well in a 96-well flat bottom plate to give 6000 cells/well.

3. Use half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, a set of 4 wells for medium control and 4 wells for DMSO control.

4. Gently shake plates to allow for uniform attachment of the cells.

5. Incubate the plates at 37°C in a 10% CO₂ incubator.

Day 1: Addition of Compound:

This part of assay is carried out in a laminar flow hood.

1. In 96 well-round bottom plate, add 125 μ l of growth medium to columns 3 to 11. This plate is used to titrate out the compound, 4 rows per compound.

2. In a sterile 15 ml tube, make a 2X solution of the highest concentration of compound by adding 8 μ l of the compound to a total of 2 ml growth medium for a dilution of 1:250. At this dilution, the concentration of DMSO is 0.4% for a 2X solution or 0.2% for 1X solution on the cells. The starting concentration of the compound is usually 100 uM but this concentration may vary depending upon the solubility of the compound.

3. Transfer the 2X starting compound solution to quadruplicate wells in column 12 of the 96-well round bottom plate. Do 1:2 serial dilutions across the plate from right to left by transferring 125 μ l from column 12 to column 11, column 11 to 10 and so on. Transfer 100 μ l of compound dilutions onto 100 μ l medium on cells in corresponding wells of 96-well flat bottom plate. Total volume per well should be 200 μ l.

4. For vehicle control, prepare a 2X solution of DMSO at 0.4% DMSO in growth medium. Transfer 100 μ l of the DMSO solution to the appropriate wells of cells. The final concentration of DMSO is 0.2%.

5. For the medium control wells, add 100 μ l/well of growth medium to the appropriate wells of cells.

6. Return the plate to the incubator and incubate for 4 days.

Day 5: Development of Assay

This part of assay is carried out on the bench.

1. Aspirate or pour off medium. Add 200 μ l cold 10% TCA to each well to fix cells. Incubate plate for at least 60 min. at 4°C.

2. Discard TCA and rinse wells 5 times with water. Dry plates upside down on paper towels.

3. Stain cells with 100 μ l/well 0.4% SRB for 10 min.

4. Pour off SRB and rinse wells 5 times with 1% acetic acid. Dry plates completely upside down on paper towels.

5. Solubilize dye with 100 μ l/well 10 mM Tris base for 5-10 min. on shaker.

6. Read plates on Dynatech ELISA Plate Reader at 570 nm with reference at 630 nm.

Assay 2: 3T3/EGF-R+TGF-a(T) Cell Growth SRB Assay

Materials and Reagents same as for Assay 1.

10 Cell line and growth medium:

3T3/EGF-R+TGF-a(T) (NIH 3T3 clone 7 cells expressing EGF-R and TGF-a, tumor-derived autocrine loop cells)
2% calf serum/DMEM + 2 mM glutamine

Protocol:

15 Day 0: Cell Plating:

This part of assay is carried out in a laminar flow hood.

1. Trypsinize cells as usual. Transfer 100 μ l of cell suspension to 10 ml of isotone. Count cells with
20 the Coulter Counter.

2. Dilute cells in growth medium to 60,000 cells/ml. Transfer 100 μ l of cells to each well in a 96-well flat bottom plate to give 6000 cells/well.

3. Use half of plate (4 rows) for each compound
25 and quadruplicate wells for each compound concentration,

a set of 4 wells for medium control and 4 wells for DMSO control.

4. Gently shake plates to allow for uniform attachment of the cells.

5 5. Incubate the plates at 37°C in a 10% CO₂ incubator.

Day 1: Addition of Compound: same as for Assay 1.

Day 5: Development of Assay: same as for Assay 1.

Assay 3: 3T3/PDGF-βR/PDGF-BB(T) Cell Growth SRB Assay

10 Cell line and growth medium:

3T3/PDGF-βR/PDGF-BB(T) (NIH 3T3 clone 7 cells expressing PDGF β-receptor and PDGF-BB, from tumors resected from athymic mice)

2% calf serum/DMEM + 2 mM glutamine

15 Protocol:

Day 0: Cell Plating:

This part of assay is carried out in a laminar flow hood.

20 1. Trypsinize cells as usual. Transfer 200 μl of cell suspension to 10 ml of isotone. Count cells on the Coulter Counter.

2. Dilute cells in growth medium to 60,000 cells/ml. Transfer 100 μl of cells to each well in a 96-well flat bottom plate to give 6000 cells/well.

3. Allow half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, a set of 4 wells for medium control and 4 wells for DMSO control.

5 4. Gently shake plates to allow for uniform attachment of the cells to the plate.

5. Incubate the plates at 37°C in a 10% CO₂ incubator.

Day 1: Addition of Compound: same as for Assay 1.

10 Day 5: Development of Assay: same as for Assay 1.

Assay 4: Human Smooth Muscle Cells (SMC) Growth SRB Assay

Materials and Reagents same as for Assay 1:

Cell line and growth medium:

15 Human Aortic Smooth Muscle cells (Clonetics)

Clonetics's Bullet Kit: Smooth Muscle Basal Medium (SmBM) which is modified MCDB 131 containing fetal bovine serum (5%), hFGF (2ng/ml), hEGF (0.1 ng/ml), insulin (5.0 ug/ml), gentamicin (50ug/ml) and
20 amphotericin B (50 ng/ml)

Protocol:

Day 0: Cell plating:

This part of assay is carried out in a laminar flow hood.

1. Trypsinize cells as usual. Transfer 200 μ l of cell suspension to 10 ml of isotone. Count cells on the Coulter Counter.
 2. Dilute cells in growth medium to 20,000 cells/ml. Transfer 100 μ l of cells to each well in a 96-well flat bottom plate to give 2000 cells/well.
 3. Allow half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, a set of 4 wells for medium control and 4 wells for DMSO control.
 4. Gently shake plates to allow for uniform attachment of the cells to the plate.
 5. Incubate the plates at 37°C in a 10% CO₂ incubator.
- Day 1: Addition of Compound: same as for Assay 1.
- Day 5: Development of Assay: same as for Assay 1.

(iii) 3T3 Cell Growth Assay

Assay 1: PDGF-Induced BrdU Incorporation Assay

Materials and Reagents:

- (1) PDGF: human PDGF B/B; 1276-956, Boehringer Mannheim, Germany
- (2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

- (3) FixDenat: fixation solution (ready to use),
Cat. No. 1 647 229, Boehringer Mannheim,
Germany.
- 5 (4) Anti-BrdU-POD: mouse monoclonal antibody
conjugated with peroxidase, Cat. No. 1 647
229, Boehringer Mannheim, Germany.
- (5) TMB Substrate Solution:
tetramethylbenzidine (TMB), ready to use, Cat.
No. 1 647 229, Boehringer Mannheim, Germany.
- 10 (6) PBS Washing Solution : 1X PBS, pH 7.4,
made in house.
- (7) Albumin, Bovine (BSA): fraction V powder; A-
8551, Sigma Chemical Co., USA.

Protocol

- 15 (1) 3T3 engineered cell line: 3T3/EGFRc7.
- (2) Cells are seeded at 8000 cells/well in
DMEM, 10% CS, 2mM Gln in a 96 well plate.
Cells are incubated overnight at 37°C in 5%
CO₂.
- 20 (3) After 24 hours, the cells are washed with
PBS, and then are serum starved in serum free
medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- (4) On day 3, ligand (PDGF=3.8 nM, prepared in
DMEM with 0.1% BSA) and test compounds are
25 added to the cells simultaneously. The
negative control wells receive serum free DMEM
with 0.1% BSA only; the positive control cells
receive the ligand (PDGF) but no test

compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.

- 5 (5) After 20 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 μ M) for 1.5 hours.
- 10 (6) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.
- 15 (7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30
- 20 minutes at room temperature on a plate shaker.
- (8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is
- 25 incubated for 90 minutes at room temperature on a plate shaker.
- (9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times

with PBS, and the plate is dried by inverting and tapping on a paper towel.

- 5 (10) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.
- 10 (11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 2: EGF-Induced BrdU Incorporation Assay

Materials and Reagents

- 15 (1) EGF: mouse EGF, 201; Toyobo, Co., Ltd. Japan
- (2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 20 (3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 25 (5) TMB Substrate Solution: tetramethylbenzidine (TMB); ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

- (6) PBS Washing Solution : 1X PBS, pH 7.4, made in house.
- (7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

5 Protocol

- (1) 3T3 engineered cell line: 3T3/EGFRc7
- (2) Cells are seeded at 8000 cells/well in 10% CS, 2mM Gln in DMEM, in a 96 well plate. Cells are incubated overnight at 37°C in 5% CO₂.
- 10 (3) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- 15 (4) On day 3, ligand (EGF=2 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (EGF) but no test compound. Test compounds are prepared in serum free DMEM
- 20 with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- 25 5) After 20 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 µM) for 1.5 hours.
- 6) After incubation with labeling reagent, the medium is removed by decanting and tapping the

inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.

- 5 (7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30
- 10 minutes at room temperature on a plate shaker.
- (8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is
- 15 incubated for 90 minutes at room temperature on a plate shaker.
- (9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting
- 20 and tapping on a paper towel.
- (10) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric
- 25 detection.
- (11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 3: EGF-Induced Her2 -Driven BrdU Incorporation**Materials and Reagents:**

- (1) EGF: mouse EGF, 201; Toyobo, Co., Ltd. Japan
- (2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4),
5 Cat. No. 1 647 229, Boehringer Mannheim,
Germany.
- (3) FixDenat: fixation solution (ready to use),
Cat. No. 1 647 229, Boehringer Mannheim,
Germany.
- 10 (4) Anti-BrdU-POD: mouse monoclonal antibody
conjugated with peroxidase, Cat. No. 1 647
229, Boehringer Mannheim, Germany.
- (5) TMB Substrate Solution: tetramethylbenzidine
(TMB), ready to use, Cat. No. 1 647 229,
15 Boehringer Mannheim, Germany.
- (6) PBS Washing Solution : 1X PBS, pH 7.4, made in
house.
- (7) Albumin, Bovine (BSA): fraction V powder; A-
8551, Sigma Chemical Co., USA.

20 Protocol:

- (1) 3T3 engineered cell line: 3T3/EGFr/Her2/EGFr
(EGFr with a Her2 kinase domain)
- (2) Cells are seeded at 8000 cells/well in DMEM,
10% CS, 2mM Gln in a 96- well plate. Cells are
25 incubated overnight at 37° in 5% CO₂.
- (3) After 24 hours, the cells are washed with PBS,
and then are serum starved in serum free
medium (0%CS DMEM with 0.1% BSA) for 24 hours.

- (4) On day 3, ligand (EGF=2 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (EGF) but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- 5
- (5) After 20 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 μ M) for 1.5 hours.
- 10
- (6) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.
- 15
- (7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.
- 20
- (8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1%
- 25

BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

5 (9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.

10 (10) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

15 (11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 4: IGF1-Induced BrdU Incorporation Assay

Materials and Reagents:

- 20 (1) IGF1 Ligand: human, recombinant; G511, Promega Corp, USA.
- (2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 25 (3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

- (4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 5 (5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (6) PBS Washing Solution : 1X PBS, pH 7.4, made in house.
- 10 (7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

Protocol:

- (1) 3T3 engineered cell line: 3T3/IGF1r.
- (2) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96- well plate. Cells are incubated overnight at 37°C in 5% CO₂.
- 15 (3) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- (4) On day 3, ligand (IGF1=3.3 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (IGF1) but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- 20
- 25

- 5) After 16 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 μ M) for 1.5 hours.
- (6) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.
- (7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.
- (8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.
- (9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.
- (10) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room

temperature on a plate shaker until color development is sufficient for photometric detection.

- 5 (11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 5: Insulin-Induced BrdU Incorporation Assay

Materials and Reagents:

- 10 (1) Insulin: crystalline, bovine, Zinc; 13007, Gibco BRL, USA.
- (2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 15 (3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 20 (5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (6) PBS Washing Solution : 1X PBS, pH 7.4, made in house.
- 25 (7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

Protocol:

- (1) 3T3 engineered cell line: H25
- (2) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96 well plate. Cells are
5 incubated overnight at 37°C in 5% CO₂.
- (3) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- (4) On day 3, ligand (Insulin=10 nM, prepared in
10 DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (Insulin) but no test
15 compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- (5) After 16 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1%
20 BSA) is added and the cells are incubated with BrdU (final concentration=10 µM) for 1.5 hours.
- (6) After incubation with labeling reagent, the medium is removed by decanting and tapping
25 the inverted plate on a paper towel. FixDenat solution is added (50 µl/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.

- (7) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.
- (8) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.
- (9) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.
- (10) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.
- (11) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

(iv) HUV-EC-C Assay

The following protocol may also be used to measure a compound's activity:

DAY 0

- 5 1. Wash and trypsinize HUV-EC-C cells (human umbilical vein endothelial cells, (American Type Culture Collection; catalogue no. 1730 CRL). Wash with Dulbecco's phosphate-buffered saline (D-PBS; obtained from Gibco BRL; catalogue no. 14190-029) 2 times at
10 about 1 ml/10 cm² of tissue culture flask. Trypsinize with 0.05% trypsin-EDTA in non-enzymatic cell dissociation solution (Sigma Chemical Company; catalogue no. C-1544). The 0.05% trypsin was made by diluting
15 0.25% trypsin/1 mM EDTA (Gibco; catalogue no. 25200-049) in the cell dissociation solution. Trypsinize with
 about 1 ml/25-30 cm² of tissue culture flask for about 5 minutes at 37°C. After cells have detached from the flask, add an equal volume of assay medium and transfer
20 to a 50 ml sterile centrifuge tube (Fisher Scientific; catalogue no. 05-539-6).
2. Wash the cells with about 35 ml assay medium in the 50 ml sterile centrifuge tube by adding the assay medium, centrifuge for 10 minutes at approximately
25 200xg, aspirate the supernatant, and resuspend with 35 ml D-PBS. Repeat the wash two more times with D-PBS, resuspend the cells in about 1 ml assay medium/15 cm² of tissue culture flask. Assay medium consists of F12K medium (Gibco BRL; catalogue no. 21127-014) + 0.5% heat-inactivated fetal bovine serum. Count the cells with a

Coulter Counter® (Coulter Electronics, Inc.) and add assay medium to the cells to obtain a concentration of $0.8-1.0 \times 10^5$ cells/ml.

3. Add cells to 96-well flat-bottom plates at 100 μ l/well or $0.8-1.0 \times 10^4$ cells/well; incubate ~24h at 37°C, 5% CO₂.

DAY 1

1. Make up two-fold drug titrations in separate 96-well plates, generally 50 μ M on down to 0 μ M. Use the same assay medium as mentioned in day 0, step 2 above. Titrations are made by adding 90 μ l/well of drug at 200 μ M (4X the final well concentration) to the top well of a particular plate column. Since the stock drug concentration is usually 20 mM in DMSO, the 200 μ M drug concentration contains 2% DMSO.

Therefore, diluent made up to 2% DMSO in assay medium (F12K + 0.5% fetal bovine serum) is used as diluent for the drug titrations in order to dilute the drug but keep the DMSO concentration constant. Add this diluent to the remaining wells in the column at 60 μ l/well. Take 60 μ l from the 120 μ l of 200 μ M drug dilution in the top well of the column and mix with the 60 μ l in the second well of the column. Take 60 μ l from this well and mix with the 60 μ l in the third well of the column, and so on until two-fold titrations are completed. When the next-to-the-last well is mixed, take 60 μ l of the 120 μ l in this well and discard it. Leave the last well with 60 μ l of DMSO/media diluent as a non-drug-containing control. Make 9 columns of

titrated drug, enough for triplicate wells each for 1) VEGF (obtained from Pepro Tech Inc., catalogue no. 100-200, 2) endothelial cell growth factor (ECGF) (also known as acidic fibroblast growth factor, or aFGF) (obtained from Boehringer Mannheim Biochemica, catalogue no. 1439 600), and assay media control. ECGF comes as a preparation with sodium heparin.

2. Transfer 50 μ l/well of the drug dilutions to the 96-well assay plates containing the $0.8-1.0 \times 10^4$ cells/100 μ l/well of the HUV-EC-C cells from day 0 and incubate ~2 h at 37°C, 5% CO₂.

3. In triplicate, add 50 μ l/well of 80 μ g/ml VEGF, 20 ng/ml ECGF, or media control to each drug condition. As with the drugs, the growth factor concentrations are 4X the desired final concentration. Use the assay media from day 0 step 2 to make the concentrations of growth factors. Incubate approximately 24 hours at 37°C, 5% CO₂. Each well will have 50 μ l drug dilution, 50 μ l growth factor or media, and 100 μ l cells, = 200 μ l/well total. Thus the 4X concentrations of drugs and growth factors become 1X once everything has been added to the wells.

DAY 2

1. Add ³H-thymidine (Amersham; catalogue no. TRK-686) at 1 μ Ci/well (10 μ l/well of 100 μ Ci/ml solution made up in RPMI media + 10% heat-inactivated fetal bovine serum) and incubate ~24 h at 37°C, 5% CO₂. Note: ³H-thymidine is made up in RPMI media because all of the other applications for which we use the ³H-thymidine

involve experiments done in RPMI. The media difference at this step is probably not significant. RPMI was obtained from Gibco BRL, catalogue no. 11875-051.

DAY 3

- 5 1. Freeze plates overnight at -20°C.

DAY 4

1. Thaw plates and harvest with a 96-well plate harvester (Tomtec Harvester 96^(R)) onto filter mats (Wallac; catalogue no. 1205-401); read counts on a
10 Wallac Betaplate^(TM) liquid scintillation counter.

(v) PDGF-R Cellular Assay

The PDGF cellular kinase assay was carried out as follows: cells are lysed in 0.2 M Hepes, 0.15 M NaCl, 10% V/V glycerol, 0.04% Triton X-100, 5 mM EDTA, 5 mM
15 sodium vanadate and 2 mM Na⁺ pyrophosphate; cell lysates are then added to an ELISA plate coated with an anti-PDGF receptor antibody (Genzyme); ELISA plates are coated at 0.5 µg of antibody/well in 150 µl of PBS for 18 hours at 4°C prior to the addition of the lysate; the
20 lysate is incubated in the coated plates for 1 hour and then washed four times in TBST (35 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.1% Triton X100); anti-phosphotyrosine antibody (100 µl in PBS) is added and the mixture is incubated for 30 minutes at room temperature; the wells
25 were then washed four times in TBST, a secondary antibody conjugated to POD (TAGO) is added to each well, and the treated well are incubated for 30 minutes at room temperature; the wells are then washed four times

in TBST, ABTS/H₂O₂ solution is added to each well and the wells are incubated for two minutes; absorbance is then measured at 410 nm.

(vi) Assay Measuring Phosphorylating Function

5 of Raf

The following assay reports the amount of RAF-catalyzed phosphorylation of its target protein MEK as well as MEK's target MAPK. The RAF gene sequence is described in Bonner et al., 1985, *Molec. Cell. Biol.* 5: 1400-1407, and is readily accessible in multiple gene
10 sequence data banks. Construction of the nucleic acid vector and cell lines utilized for this portion of the invention are fully described in Morrison et al., 1988, *Proc. Natl. Acad. Sci. USA* 85: 8855-8859.

15 Materials and Reagents

1. Sf9 (*Spodoptera frugiperda*) cells; GIBCO-BRL, Gaithersburg, MD.
2. RIPA buffer: 20 mM Tris/HCl pH 7.4, 137 mM NaCl, 10 % glycerol, 1 mM PMSF, 5 mg/L Aprotinin, 0.5
20 % Triton X-100;
3. Thioredoxin-MEK fusion protein (T-MEK): T-MEK expression and purification by affinity chromatography were performed according to the manufacturer's procedures. Catalog# K 350-01 and R 350-
25 40, Invitrogen Corp., San Diego, CA
4. His-MAPK (ERK 2); His-tagged MAPK was expressed in XL1 Blue cells transformed with pUC18

vector encoding His-MAPK. His-MAPK was purified by Ni-affinity chromatography. Cat# 27-4949-01, Pharmacia, Alameda, CA

- 5 5. Sheep anti mouse IgG: Jackson
laboratories, West Grove, PA Catalog, # 515-006-008,
Lot# 28563
6. Sumo 22: Monoclonal antibody Sumo 22 (URP
30 S 3) specific for the RAF-1 protein kinase
- 10 7. Coating buffer: PBS; phosphate buffered
saline, GIBCO-BRL, Gaithersburg, MD
8. Wash buffer: TBST - 50 mM Tris/HCL pH
7.2, 150 mM NaCl, 0.1 % Triton X-100
9. Block buffer: TBST, 0.1 % ethanolamine pH
7.4
- 15 10. DMSO, Sigma, St. Louis, MO
11. Kinase buffer (KB): 20 mM Hepes/HCL pH
7.2, 150 mM NaCl, 0.1 % Triton X-100, 1 mM PMSF, 5
mg/L Aprotinin, 75 μ M sodium ortho vanadate, 0.5 mM
DTT and 10 mM $MgCl_2$.
- 20 12. ATP mix: 100 mM $MgCl_2$, 300 μ M ATP, 10 μ Ci
 γ - ^{33}P ATP (Dupont-NEN)/mL.
13. Stop solution: 1 % phosphoric acid;
Fisher, Pittsburgh, PA.
14. Wallac Cellulose Phosphate Filter
25 mats; Wallac, Turku, Finland.
15. Filter wash solution: 1 % phosphoric
acid, Fisher, Pittsburgh, PA.
16. Tomtec plate harvester, Wallac, Turku,
Finland.

17. Wallac beta plate reader # 1205, Wallac, Turku, Finland.

18. NUNC 96-well V bottom polypropylene plates for compounds Applied Scientific Catalog # AS-
5 72092.

Procedure

All of the following steps are conducted at room temperature unless specifically indicated.

1. ELISA plate coating: ELISA wells are
10 coated with 100 μ L of Sheep anti mouse affinity purified antiserum (1 μ g/100 μ L coating buffer) over night at 4 $^{\circ}$ C. ELISA plates can be used for two weeks when stored at 4 $^{\circ}$ C.

2. Invert the plate and remove liquid. Add
15 100 μ L of blocking solution and incubate for 30 min.

3. Remove blocking solution and wash four times with wash buffer. Pat the plate on a paper towel to remove excess liquid.

4. Add 1 μ g of purified Sumo 22 to each well
20 and incubate for 1 hour. Wash as described in step 3.

5. Thaw lysates from RAS/RAF infected Sf9 cells and dilute with TBST to 10 μ g/100 μ L. Add 10 μ g of diluted lysate to the wells and incubate for 1 hour. Shake the plate during incubation. Negative controls
25 receive no lysate. Lysates from RAS/RAF infected Sf9 insect cells are prepared after cells are infected with recombinant baculoviruses at a MOI of 5 for each virus, and harvested 48 hours later. The cells are washed once

with PBS and lysed in RIPA buffer. Insoluble material is removed by centrifugation (5 min at 10 000 x g). Aliquots of lysates are frozen in dry ice/ethanol and stored at - 80 °C until use.

5 6. Remove non-bound material and wash as outlined above (step 3).

 7. Add 2 µg of T-MEK and 2 µg of His-MAPK per well and adjust the volume to 40 µL with kinase buffer.

10 8. Predilute compounds (stock solution 10 mg/mL DMSO) or extracts 20 fold in TBST plus 1% DMSO. Add 5 µL of the prediluted compounds/extracts to the wells described in step 6. Incubate for 20 min. Controls receive no drug.

15 9. Start the kinase reaction by addition of 5 µL ATP mix; Shake the plates on an ELISA plate shaker during incubation.

 10. Stop the kinase reaction after 60 min by addition of 30 µL stop solution to each well.

20 11. Place the phosphocellulose mat and the ELISA plate in the Tomtec plate harvester. Harvest and wash the filter with the filter wash solution according to the manufacturers recommendation. Dry the filter mats. Seal the filter mats and place them in the
25 holder. Insert the holder into radioactive detection apparatus and quantitate the radioactive phosphorous on the filter mats.

 Alternatively, 40 µL aliquots from individual wells of the assay plate can be transferred to the

corresponding positions on the phosphocellulose filter mat. After air-drying the filters, put the filters in a tray. Gently rock the tray, changing the wash solution at 15 min intervals for 1 hour. Air-dry the filter mats. Seal the filter mats and place them in a holder suitable for measuring the radioactive phosphorous in the samples. Insert the holder into a detection device and quantitate the radioactive phosphorous on the filter mats.

10 (c) Measurement Of Cell Toxicity

Therapeutic compounds should be more potent in inhibiting receptor tyrosine kinase activity than in exerting a cytotoxic effect. A measure of the effectiveness and cell toxicity of a compound can be obtained by determining the therapeutic index: IC_{50}/LD_{50} . IC_{50} , the dose required to achieve 50% inhibition, can be measured using standard techniques such as those described herein. LD_{50} , the dosage which results in 50% toxicity, can also be measured by standard techniques (Mossman, 1983, *J. Immunol. Methods*, 65:55-63), by measuring the amount of LDH released (Korzeniewski and Callewaert, 1983, *J. Immunol. Methods* 64:313; Decker and Lohmann-Matthes, 1988, *J. Immunol. Methods* 115:61), or by measuring the lethal dose in animal models.

25 Compounds with a large therapeutic index are preferred. The therapeutic index should be greater than 2, preferably at least 10, more preferably at least 50.

EXAMPLE 3: IN VIVO ANIMAL MODELS**(i) Xenograft Animal Models**

The ability of human tumors to grow as xenografts in athymic mice (e.g., Balb/c, nu/nu) provides a useful in vivo model for studying the biological response to therapies for human tumors. Since the first successful xenotransplantation of human tumors into athymic mice, (Rygaard and Povlsen, 1969, *Acta Pathol. Microbial. Scand.* 77:758-760), many different human tumor cell lines (e.g., mammary, lung, genitourinary, gastrointestinal, head and neck, glioblastoma, bone, and malignant melanomas) have been transplanted and successfully grown in nude mice. Human mammary tumor cell lines, including MCF-7, ZR75-1, and MDA-MB-231, have been established as subcutaneous xenografts in nude mice (Warri et al., 1991, *Int. J. Cancer* 49:616-623; Ozzello and Sordat, 1980, *Eur. J. Cancer* 16:553-559; Osborne et al., 1985, *Cancer Res.* 45:584-590; Seibert et al., 1983, *Cancer Res.* 43:2223-2239).

Assay 1: HER2/Xenograft Animal Model

To study the effect of anti-tumor drug candidates on HER2 expressing tumors, the tumor cells should be able to grow in the absence of supplemental estrogen. Many mammary cell lines are dependent on estrogen for in vivo growth in nude mice (Osborne et al., *supra*), however, exogenous estrogen suppresses HER2 expression in nude mice (Warri et al., *supra*, Dati et al., 1990,

Oncogene 5:1001-1006). For example, in the presence of estrogen, MCF-7, ZR-75-1, and T47D cells grow well *in vivo*, but express very low levels of HER2 (Warri et al., *supra*, Dati et al., *supra*).

5 The following type of xenograft protocol can be used:

- 1) implant tumor cells (subcutaneously) into the hindflank of five- to six-week-old female Balb/c nu/nu athymic mice;
- 10 2) administer the anti-tumor compound;
- 3) measure tumor growth by measuring tumor volume.

 The tumors can also be analyzed for the presence of a receptor, such as HER2, EGF or PDGF, by Western and
15 immunohistochemical analyses. Using techniques known in the art, one skilled in the art can vary the above procedures, for example through the use of different treatment regimes.

Assay 2: FLK-1/Xenograft Model.

20 The ability of the compounds of the present invention to inhibit ovarian, melanoma, prostate, lung and mammary tumor cell lines established as SC xenografts was examined. These studies were conducted using doses ranging from 1 to 75 mg/kg/day.

25 **Materials And Methods.** The tumor cells were implanted subcutaneously into the indicated strains of mice. Treatment was initiated on day 1 post implantation unless otherwise indicated (e.g. treatment

of the SCID mouse related to the A375 melanoma cell line began on Day 9). Eight (8) to sixteen (16) mice comprised each test group.

Specifically:

5 *Animals.* Female athymic mice (BALB/c, nu/nu), BALB/c mice, Wistar rats and Fisher 344 rats were obtained from Simonsen Laboratories (Gilroy, CA). Female A/I mice were obtained from Jackson Laboratory (Bar Harbor, ME). DA rats were obtained from B&K
10 Universal, Inc. (Fremont, CA). Athymic R/Nu rats, DBA/2N mice, and BALB/c mice were obtained from Harlan Sprague Dawley (Indianapolis, IN). Female C57BL/6 mice were obtained from Taconic (Germantown, NY). All animals were maintained under clean-room conditions in
15 Micro-isolator cages with Alpha-dri bedding. They received sterile rodent chow and water *ad libitum*.

All procedures were conducted in accordance with the *NIH Guide for the Care and Use Of Laboratory Animals*.

Subcutaneous Xenograft Model. Cell lines were
20 grown in appropriate medium as described (See Section 6). Cells were harvested at or near confluency with 0.05% Trypsin-EDTA and pelleted at 450 x g for 10 min. Pellets were resuspended in sterile PBS or media (without FBS) to a suitable concentration indicated in
25 the Figure legends and the cells were implanted into the hindflank of mice. Tumor growth was measured over 3 to 6 weeks using venier calipers tumor volumes were calculated as a product of length x width x height unless otherwise indicated. P values were calculated

using the Students' t-test. Compound in 50 - 100 μ L excipient (dimethylsulfoxide, PBTE, PBTE6C:D5W, or PBTE:D5W) was delivered by IP injection at concentrations indicated in the Figure legends.

5 *Intracerebral Xenograft Model.* For the mouse IC model, rat C6 glioma cells were harvested and suspended in sterile PBS at a concentration of 2.5×10^7 cells/ml and placed on ice. Cells were implanted into BALB/c, nu/nu mice in the following manner: the
10 frontoparietal scalps of mice were shaved with animal clippers if necessary before swabbing with 70% ethanol. Animals were anesthetized with isofluorane and the needle was inserted through the skull into the left hemisphere of the brain. Cells were dispensed from
15 Hamilton Gas-tight Syringes using 30 ga $\frac{1}{8}$ inch needles fitted with sleeves that allowed only a 3 mm penetration. A repeater dispenser was used for accurate delivery of 4 μ L of cell suspension. Animals were monitored daily for well-being and were sacrificed when
20 they had a weight loss of about 40% and/or showed neurological symptoms.

For the rat IC model, rats (Wistar, Sprague Dawley, Fisher 344, or athymic R/Nu; approximately 200-400 g (some 3-400g)) were anesthetized by an IP injection of
25 100 mg/kg Ketaset (ketamine hydrochloride; Aveco, Fort Dodge, Iowa) and 5 mg/kg Rompun (xylazine, 2% solution; Bayer, Germany). After onset of anesthesia, the scalp was shaved and the animal was oriented in a stereotaxic apparatus (Stoelting, Wood Dale, IL). The skin at the

incision site was cleaned 3 times with alternating swabs of 70% ethanol and 10% Povidone-Iodine. A median 1.0 - 1.5 cm incision was made in the scalp using a sterile surgical blade. The skin was detached slightly and pulled to the sides to expose the sutures on the skull surface. A dental drill (Stoelting, Wood Dale, IL) was used to make a small (1-2 mm diameter) burrhole in the skull approximately 1 mm anterior and 2 mm lateral to the bregma. The cell suspension was drawn into a 50 μ L Hamilton syringe fitted with a 23 or 25g standard bevel needle. The syringe was oriented in the burrhole at the level of the arachnoidea and lowered until the tip of the needle was 3 mm deep into the brain structure, where the cell suspension was slowly injected. After cells were injected, the needle was left in the burrhole for 1-2 minutes to allow for complete delivery of the cells. The skull was cleaned and the skin was closed with 2 to 3 sutures. Animals were observed for recovery from surgery and anesthesia. Throughout the experiment, animals were observed at least twice each day for development of symptoms associated with progression of intracerebral tumor. Animals displaying advanced symptoms (leaning, loss of balance, dehydration, loss of appetite, loss of coordination, cessation of grooming activities, and/or significant weight loss) were humanely sacrificed and the organs and tissues of interest were resected.

Intraperitoneal Model. Cell lines were grown in the appropriate media. Cells were harvested and

washed in sterile PBS or medium without FBS, resuspended to a suitable concentration, and injected into the IP cavity of mice of the appropriate strain. Mice were observed daily for the occurrence of ascites formation.

5 Individual animals were sacrificed when they presented with a weight gain of 40%, or when the IP tumor burden began to cause undue stress and pain to the animal.

(ii) In Vivo VEGF Pellet Model

In the following example, the Pellet Model was used to test a compound's activity against the FLK-1 receptor and against disorders associated with the formation of blood vessels. In this model, VEGF is packaged into a time-release pellet and implanted subcutaneously on the abdomen of nude mice to induce a 'reddening' response and subsequent swelling around the pellet. Potential FLK-1 inhibitors may then be implanted in methylcellulose near the VEGF pellet to determine whether such inhibitor may be used to inhibit the "reddening" response and subsequent swelling.

10 used to test a compound's activity against the FLK-1 receptor and against disorders associated with the formation of blood vessels. In this model, VEGF is packaged into a time-release pellet and implanted subcutaneously on the abdomen of nude mice to induce a 'reddening' response and subsequent swelling around the pellet. Potential FLK-1 inhibitors may then be implanted in methylcellulose near the VEGF pellet to determine whether such inhibitor may be used to inhibit the "reddening" response and subsequent swelling.

15

Materials And Methods. The following materials were used:

20

1) VEGF- human recombinant lyophilized product is commercially may be obtained from Peprotech, Inc., Princeton Business Park, G2; P.O. box 275, Rocky Hill, NJ 08553.

25

2) VEGF packaged into 21 day release pellets were obtained from Innovative Research of America (Innovative Research of America, 3361 Executive Parkway, P.O. Box

2746, Toledo, Ohio 43606), using patented matrix driven delivery system. Pellets were packaged at 0.20, 0.21, or 2.1 μ g VEGF/pellet. These doses approximate 10 and 100 ng/day release of VEGF.

- 5 3) Methylcellulose
- 4) Water (sterile)
- 5) Methanol
- 6) Appropriate drugs/inhibitors
- 7) 10 cm culture plates
- 10 8) parafilm

The following protocol was then followed to conduct the VEGF pellet model:

- 1) VEGF, purchased from Peprotech, was sent to Innovative Research for Custom Pellet preparation;
- 15 2) Methylcellulose prepared at 1.5% (w/v) in sterile water;
- 3) Drugs solubilized in methanol (usual concentration range = 10 to 20 mg/ml);
- 4) Place sterile parafilm in sterile 10 cm
- 20 plates;
- 5) 150 μ l of drug in methanol added to 1.35 ml of 1.5% methylcellulose and mixed/vortexed thoroughly;
- 6) 25 μ l aliquots of homogenate placed on parafilm and dried into discs;
- 25 7) Mice (6-10 wk. Balb/C athymic nu/nu, female) were anesthetized via isoflurane inhalation; 8)
- VEGF pellets and methylcellulose discs were implanted subcutaneously on the abdomen; and

9) Mice were scored at 24 hours and 48 hours for reddening and swelling response.

The specific experimental design used in this example was:

- 5 N = 4 animals/group
- Controls: VEGF pellet + drug placebo
- VEGF placebo + drug pellet

(iii) Mammary Fat Pad Model

Because of the established role played by many
10 of the RTKs, e.g., the HER2 receptor, in breast cancer, the mammary fat pad model is particularly useful for measuring the efficacy of compounds which inhibit such RTKs. By implanting tumor cells directly into the location of interest, *in situ* models more accurately
15 reflect the biology of tumor development than do subcutaneous models. Human mammary cell lines, including MCF-7, have been grown in the mammary fat pad of athymic mice. Shafie and Grantham, 1981, *Natl. Cancer Instit.* 67:51-56; Gottardis et al., 1988, *J. Steroid Biochem.* 30:311-314. More specifically, the
20 following procedure can be used to measure the inhibitory effect of a compound on the HER2 receptor:

- 1) Implant, at various concentrations, MDA-MB-231 and MCF-7 cells transfected with HER-2 into
25 the axillary mammary fat pads of female athymic mice;
- 2) Administer the compound; and

- 3) Measure the tumor growth at various time points.

The tumors can also be analyzed for the presence of a receptor such as HER2, by Western and immunohistochemical analyses. Using techniques known in the art, one skilled in the art can vary the above procedures, for example through the use of different treatment regimes.

(iv) Tumor Invasion Model

The following tumor invasion model has been developed and may be used for the evaluation of therapeutic value and efficacy of the compounds identified to selectively inhibit KDR/FLK-1 receptor.

(A) Procedure

8 week old nude mice (female) (Simonsen Inc.) were used as experimental animals. Implantation of tumor cells was performed in a laminar flow hood. For anesthesia, Xylazine/Ketamine Cocktail (100 mg/kg ketamine and 5 mg/kg) are administered intraperitoneally. A midline incision is done to expose the abdominal cavity (approximately 1.5 cm in length) to inject 10^7 tumor cells in a volume of 100 μ l medium. The cells are injected either into the duodenal lobe of the pancreas or under the serosa of the colon. The peritoneum and muscles are closed with a 6-0 silk continuous suture and the skin was closed by using wound clips. Animals were observed daily.

(B) Analysis

After 2-6 weeks, depending on gross observations of the animals, the mice are sacrificed, and the local tumor metastases, to various organs (lung, liver, brain, stomach, spleen, heart, muscle) are excised and analyzed (measurements of tumor size, grade of invasion, immunochemistry, and in situ hybridization).

The invention illustratively described herein may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

Those references not previously incorporated herein by reference, including both patent and non-patent

references, are expressly incorporated herein by reference for all purposes.

Other embodiments are encompassed by the following claims.

CLAIMS

What Is Claimed Is:

1. Method for modulating the activity of a protein kinase comprising the step of contacting said
5 protein kinase with an indolinone compound demonstrated to have modulating capability in a bioassay corresponding to said protein kinase.

2. The method of claim 1, wherein said protein kinase is a serine kinase.

10 3. The method of claim 1, wherein said protein kinase is a threonine kinase.

4. The method of claim 1, wherein said protein kinase is a tyrosine kinase.

15 5. The method of claim 4, wherein said tyrosine kinase is a split kinase.

6. The method of claim 4, wherein said tyrosine kinase is a non-split kinase.

7. The method of claim 1, wherein said bioassay is a Flk bioassay.

103

8. The method of claim 1, wherein said bioassay is an EGF bioassay.

9. The method of claim 1, wherein said bioassay is a HER2 bioassay.

5 10. The method of claim 1, wherein said bioassay is a PCRB bioassay.

11. The method of claim 1, wherein said bioassay is a BLOKIN bioassay.

10 12. The method of claim 1, wherein said bioassay is a rafmak bioassay.

13. The method of claim 1, wherein said method is performed in vitro.

14. The method of claim 1, wherein said method is performed in vivo.

15 15. The method of claim 14, wherein said method at least partially alleviates or prevents one or more symptoms associated with a cell proliferation or cell differentiation disorder.

20 16. The method of claim 15, wherein said protein kinase is a PDGFR kinase and said disorder is selected from the group consisting of cancer, arterial

restenosis, fibrotic disease of the lung, kidney or liver, and wound scarring.

17. The method of claim 15, wherein said protein kinase is a FLk kinase and said disorder is
5 selected from the group consisting of cancer, metastatic disease, rheumatoid arthritis, psoriasis, diabetic retinopathy, and age-related macular degeneration.

18. The method of claim 15, wherein said protein kinase is an EGFR or HER2 kinase and said
10 disorder is selected from the group consisting of cancer and psoriasis.

19. The method of claim 15, wherein said protein kinase is a raf kinase and said disorder is
15 selected from the group consisting of cancer, hyperplasia in arterial restinosis, transplant rejection, inflammation, and psoriasis.

20. A pharmaceutical composition comprising an compound of Table 1 and a physiologically acceptable carrier or diluent.

20 21. A method of preventing or treating an abnormal condition in an organism, where the abnormal condition is associated with an aberration in a signal transduction pathway characterized by an interaction

between a protein kinase and a natural binding partner,
where the method comprises the following steps:

- (a) administering a compound of Table 1 to an
organism; and
- 5 (b) promoting or disrupting the abnormal
interaction.

22. The method of claim 21, where the
organism is a mammal.

23. The method of claim 21, where the protein
10 kinase is a *FLK* protein kinase.

24. The method of claim 21, where the protein
kinase is a platelet derived growth factor receptor
protein kinase.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/40	A3	(11) International Publication Number: WO 98/24432 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/22210 (22) International Filing Date: 2 December 1997 (02.12.97) (30) Priority Data: 60/031,587 5 December 1996 (05.12.96) US 60/045,716 6 May 1997 (06.05.97) US (71) Applicant (for all designated States except US): SUGEN, INC. [US/US]; 351 Galveston Drive, Redwood City, CA 94063-4720 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): McMAHON, Gerald [US/US]; 1800 Schultz Road, Kenwood, CA 95454 (US). TANG, Peng, Cho [US/US]; 827 Camino Ricardo, Moraga, CA 94556 (US). SUN, Li [CN/US]; 64 Rockharbor Lane, Foster City, CA 94404 (US). TRAN, Ngoc, My [GB/US]; Apartment 6306, 550 Shannon Way, Redwood City, CA 94065 (US). (74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 13 August 1998 (13.08.98)
(54) Title: USE OF INDOLINONE COMPOUNDS AS MODULATORS OF PROTEIN KINASES (57) Abstract The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/22210

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 98 07695 A (HIRTH KLAUS PETER ;SHAWVER LAURA KAY (US); SUGEN INC (US); TANG PE) 26 February 1998 see page 1-6 see page 53, line 18 - page 56, line 22; tables & US 08/702,322 1996, cited in the application ---	1-24
P,X	WO 97 34920 A (SUGEN INC) 25 September 1997 see page 21 - page 24, line 13 ---	1-24
P,X	WO 96 40116 A (SUGEN INC) 19 December 1996 see page 1-10; claims & US 485,323, 1995, cited in the application ---	1-24
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

18 May 1998

Date of mailing of the international search report

24.06.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Orviz Diaz, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/22210

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 32380 A (PHARMACIA SPA ;BATTISTINI CARLO (IT); BALLINARI DARIO (IT); ERMOLI) 17 October 1996 see page 1 see page 16, line 6 - page 18, line 15; claims ---	1-24
X	WO 96 22976 A (PHARMACIA SPA ;BUZZETTI FRANCO (IT); BRASCA MARIA GABRIELLA (IT);) 1 August 1996 cited in the application see page 24-32; claims ---	1-24
X	WO 95 17181 A (PHARMACIA SPA) 29 June 1995 see claims ---	1-24
X	WO 95 01349 A (ERBA CARLO SPA) 12 January 1995 see page 16, line 13 - page 22, line 15 ---	1-24
X	WO 93 01182 A (ERBA CARLO SPA) 21 January 1993 see claims ---	1-24
X	WO 91 13055 A (ERBA CARLO SPA) 5 September 1991 see page 14, line 6 - line 15 ---	1-24
X	EP 0 252 713 A (PFIZER) 13 January 1988 see page 1, line 1-5 ---	1-24
X	US 4 002 749 A (ROVNYAK GEORGE C) 11 January 1977 see column 6, line 64 - column 7, line 10 ---	1-24
P,X	M. MOHAMMADI: "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors" SCIENCE, vol. 276, no. 5314, May 1997, pages 955-960, XP002065235 see the whole document -----	1-24

INTERNATIONAL SEARCH REPORT

I national application No.
PCT/US 97/22210

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 1-12, 14-19 and 21-24 are directed to a method of treatment of the human body. The search focused on the therapeutic indications of the compounds.
2. ☒ Claims Nos.: 1-24 (incompletely searched)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/22210

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 1-24 (incompletely searched)

The expression "indolinone compound" covers an extremely large number of compounds, which makes a complete search impossible. Furthermore, the reference made in claim 20 to the 1304 indolinones listed in table 1 is not allowable, according to Rule 6.2 (a) PCT. Consequently, the search had to be limited to the general inventive idea underlying the application.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 97/22210

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9807695 A	26-02-1998	NONE	
WO 9734920 A	25-09-1997	AU 2066797 A	10-10-1997
WO 9640116 A	19-12-1996	AU 6044196 A CA 2192797 A EP 0769947 A NO 965377 A	30-12-1996 19-12-1996 02-05-1997 12-02-1997
WO 9632380 A	17-10-1996	EP 0764152 A JP 10501821 T	26-03-1997 17-02-1998
WO 9622976 A	01-08-1996	AU 4436396 A CA 2186508 A EP 0752985 A JP 9510993 T	14-08-1996 01-08-1996 15-01-1997 04-11-1997
WO 9517181 A	29-06-1995	AU 676958 B AU 8061294 A CA 2155098 A EP 0684820 A HU 73176 A JP 8507089 T NO 953146 A PL 310379 A US 5576330 A ZA 9410204 A	27-03-1997 10-07-1995 29-06-1995 06-12-1995 28-06-1996 30-07-1996 10-08-1995 11-12-1995 19-11-1996 10-11-1995
WO 9501349 A	12-01-1995	AU 679754 B AU 6971994 A CA 2142472 A CN 1111454 A EP 0658159 A FI 950859 A HU 72047 A JP 8500847 T MX 9404885 A NZ 267423 A PL 307741 A US 5656654 A	10-07-1997 24-01-1995 12-01-1995 08-11-1995 21-06-1995 24-02-1995 28-03-1996 30-01-1996 31-01-1995 26-03-1996 12-06-1995 12-08-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Application No

PCT/US 97/22210

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9501349 A		ZA 9404730 A	13-07-1995
WO 9301182 A	21-01-1993	AU 656015 B	19-01-1995
		AU 2277792 A	11-02-1993
		CA 2091058 A	13-01-1993
		EP 0525472 A	03-02-1993
		EP 0552329 A	28-07-1993
		FI 931061 A	10-03-1993
		HU 67496 A	28-04-1995
		IL 102383 A	30-09-1997
		JP 6501494 T	17-02-1994
		MX 9204008 A	01-01-1993
		NZ 243454 A	24-02-1995
		RU 2072989 C	10-02-1997
		US 5409949 A	25-04-1995
WO 9113055 A	05-09-1991	AT 131470 T	15-12-1995
		AU 652740 B	08-09-1994
		AU 7241291 A	18-09-1991
		CA 2053253 A	29-08-1991
		DE 69115379 D	25-01-1996
		DE 69115379 T	15-05-1996
		EP 0470221 A	12-02-1992
		EP 0662473 A	12-07-1995
		ES 2083569 T	16-04-1996
		HU 210791 B	28-07-1995
		IE 73666 B	02-07-1997
		IL 97049 A	31-10-1995
		JP 4506081 T	22-10-1992
		NZ 237182 A	23-12-1993
		PT 96897 A	31-10-1991
		RU 2091369 C	27-09-1997
		US 5374652 A	20-12-1994
		US 5488057 A	30-01-1996
		US 5627207 A	06-05-1997
EP 0252713 A	13-01-1988	WO 9312786 A	08-07-1993
		US 4960785 A	02-10-1990
		DK 355287 A	08-04-1988
		IE 59995 B	18-05-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/22210

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0252713 A		JP 1915546 C	23-03-1995
		JP 6043393 B	08-06-1994
		JP 63023863 A	01-02-1988
		PT 85294 B	30-04-1990
		US 5064852 A	12-11-1991

US 4002749 A	11-01-1977	NONE	
